Original Article Efficacy of dexmedetomidine on postoperative nausea and vomiting: a meta-analysis of randomized controlled trials

Xiao Liang^{1*}, Miao Zhou^{2*}, Jiao-Jiao Feng^{3*}, Liang Wu², Shang-Ping Fang⁴, Xin-Yu Ge⁵, Hai-Jing Sun⁴, Peng-Cheng Ren⁶, Xin Lv⁷

¹Department of Anesthesiology, Affiliated People's Hospital of Jiangsu University; ²Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical College; Jiangsu Province Key Laboratory of Anesthesia, and Analgesia Application Technology, Xuzhou Medical College; ³Department of Medical Microbiology and Parasitology, School of Basic Medicine, Second Military Medical University; ⁴Department of Anesthesiology, Changzheng Hospital, The Second Military Medical University; ⁵Hebei North University School of Medicine; ⁶Department of Anesthesiology, Affiliated Tangdu Hospital of The Fourth Military Medical University; ⁷Department of Anesthesiology, Shanghai Pulmonary Hospital, Tongji University, School of Medicine. ^{*}Equal contributors.

Received June 9, 2015; Accepted June 11, 2015; Epub June 15, 2015; Published June 30, 2015

Abstract: Purpose: Postoperative nausea and vomiting (PONV) is a frequent complication in postoperative period. The aim of the current meta-analysis was to assess the efficacy of dexmedetomidine on PONV. Methods: Two researchers independently searched PubMed, Embase and Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs). The meta-analysis was performed with Review Manager. Results: Eighty-two trials with 6,480 patients were included in this meta-analysis. Dexmedetomidine reduced postoperative nausea (Risk Ratio (RR) = 0.61, 95% confidence interval (CI): 0.50 to 0.73) and vomiting (RR = 0.48, 95% CI: 0.36 to 0.64) compared with placebo, with an effective dose of 0.5 μ g/kg (RR = 0.46, 95% CI: 0.34 to 0.62) and 1.0 μ g/kg (RR = 0.29, 95% CI: 0.12 to 0.75), respectively. The antiemetic effect can only be achieved intravenously, not epidurally or intrathecally. The efficacy of dexmedetomidine was similar to that of widely used agents, such as propofol, midazolam etc., but better than opioid analgesics. Moreover, application of dexmedetomidine reduced intraoperative requirement of fentanyl (Standard Mean Difference = -1.91, 95% CI: -3.20 to -0.62). Conclusions: The present meta-analysis indicates that dexmedetomidine shows superiority to placebo, but not to all other anesthetic agents on PONV. And this efficacy may be related to a reduced consumption of intraoperative opioids.

Keywords: Dexmedetomidine, meta-analysis, nausea, vomiting

Introduction

Postoperative nausea and vomiting (PONV) are unwished outcomes after sedation or anesthesia, which can result in unplanned admission or delay hospital discharge [1]. Meanwhile vomiting can stress wounds, cause electrolyte imbalance and bleeding [2]. Therefore patients rate PONV as one of the least desirable events after surgeries [3], especially laparoscopy, laparotomy, and strabismus surgeries [4]. Additionally, four clear risk factors have been shown to independently predict PONV: female gender, postoperative opioid treatment, prior history of motion sickness and/or PONV and non-smoker, which increased risk by 20% respectively [5]. The risks of PONV may also vary with: preanaesthetic medication, anesthetic techniques, postoperative pain management [1].

Dexmedetomidine, with sedative, analgesic [6], sympatholytic and amnestic [7] properties is a potent and highly selective α_2 -adrenoceptor agonist, which binds to transmembrane G protein-binding receptor, and has no activity on the γ -aminobutyric acid (GABA) system [8]. And clinical researchers have already studied the administration of dexmedetomidine to prevent PONV. Nevertheless, controversy about the effectiveness of dexmedetomidine for the arrest of PONV is still ongoing, for different results reported in associated literature.

To our knowledge, there was no quantitative analysis done for the combination of related data primarily. Therefore, we conducted the current meta-analysis aiming to explore the use of dexmedetomidine as an efficacious antiemetic agent.

Methods

This meta-analysis aiming to assess the role of dexmedetomidine on PONV was performed decently according to the recommendations of the PRISMA statement. Because nausea and vomiting were defined as two separate phenomena, studies should report and evaluate the variables distinctly [9]. While since few patients experience vomiting without nausea, the incidence of PONV and postoperative nausea (PON) is fairly similar, thus original papers often do not try to distinguish these variables [10]. So, if PONV but not PON was reported in trails, we considered the PONV variables as a very close substitute for PON: when both PONV and PON were reported simultaneously, we assessed the nausea values. The most commonly used time interval to measure the role of antiemetic is 24 hours [9]. When only longer or shorter time interval was reported, we used the time interval which was closest to the 24-hour interval.

Search strategy

Two authors (L.X. and Z.M.) systematically searched Cochrane Central Register of Controlled Trials (CENTRAL), Embase and PubMed. The search strategy comprised the following key words: (dexmedetomidine) and (nausea, vomiting or PONV) and (anaesthesia, anesthesia, surgery, operation or postoperative). The literature search was updated on December 31, 2014 with no language limitation. The reference lists of the reviews, original reports and case reports (retrieved through the electronic searches) were checked to identify studies that had not yet been included in the computerized databases.

Study selection and data retrieval

The study selection criteria were pre-established. Inclusion criteria: (1) Randomized controlled trial; (2) The administration of dexmedetomidine preoperatively, intraoperatively or postoperatively; (3) The presence of nausea or vomiting reported; (4) Dexmedetomidine versus placebo or a single agent. Exclusion criteria: (1) Duplications or abstracts only; (2) Missing data; (3) Patients with severe cerebrovascular disease or other contraindications of dexmedetomidine; (4) Incorrect statistical analysis performed in the report; (5) Agent/agents (including dexmedetomidine) versus combinational agents. Data retrieval: name of the first author, publication year, funding, interventions, patients, type of anesthesia and surgery, length of operation, number of nausea and vomiting cases and total patients. Two authors (L.X. and Z.M.) independently assessed the articles for compliance with the inclusion/exclusion criteria. Any of disputes about this meta-analysis was settled promptly by discussion among all of the authors.

Qualitative assessment

Two authors (F.J.J. and W.L.) evaluated the quality of the trials independently according to the guideline recommended by the Cochrane Collaboration [11]. Six categories (randomization sequence generation, blinding method, allocation concealment, incomplete outcome data, selective reporting, other bias, with the first three categories considered as "key domains") were assessed, each one summarized into three levels: high risk, unclear risk, and low risk. The risk of bias of each study was evaluated according to the levels of the three key domains: "High" (high risk of bias for one or more key domains), "Unclear" (unclear risk of bias for one or more key domains), and "Low" (low risk of bias for all key domains).

Statistical analysis

The efficacy of dexmedetomidine on nausea and vomiting, compared with placebo or other anesthetic drugs, was estimated by calculating pooled Risk Ratio (RR), and the consumption of intraoperative fentanyl was assessed by pooled Standard Mean Difference (SMD), with 95% confidence intervals (Cl). The overall effect was determined by Z test (P < 0.05 was considered statistically significant). A fixed effects model was adopted when $l^2 \leq 50\%$, otherwise, a random effects model was used.

Sensitivity analysis was performed to test the robustness of these results, by reanalyzing the data of low-risk and unclear-risk studies only. Subgroup analyses were based on the type of anesthesia, route of administration, investigator initiated trail, dosage regimen, dose of dexmedetomidine, high-risk factor of PONV and other anesthetic agents.



Figure 1. Flow diagram of the inclusion and exclusion process.

Begg's Test was conducted to assess potential publication bias. Statistical analysis was performed with Stata[®] (Version 12.0; Stata Corp, TX, USA) and Review Manager (RevMan[®]) (Version 5.3; The Cochrane Collaboration, Oxford, UK).

Result

Study selection

As shown in the flow diagram (**Figure 1**), the search of PubMed, Embase, CENTRAL and reference lists yielded 780 articles. Initially, 431 trials were discarded because they were not controlled trials by reading the titles. Then, 46 were excluded for not relevant to our study by reviewing the abstracts. Two full-texts [12, 13] of the remaining 104 papers couldn't be retrieved in spite of efforts by interlibrary loan, electric retrieval and contacting the authors. One hundred and two papers were carefully read, and we found no related endpoints were reported in 20 papers, so they were excluded. Finally, 82 trials [14-95] that met the selection criteria were included in the meta-analysis.

Study characteristic

Of all the included studies, 49 trials [14-62] explored the efficacy of dexmedetomidine compared with placebo. Other control agents

included fentanyl [23, 48, 68, 73, 78, 80, 86, 87, 93], remifentanyl [77, 82, 84, 91, 95], morphine [69, 72, 81, 83], propofol [34, 63, 67, 70, 88, 94], midazolam [65, 66, 74, 76, 85, 89, 90], clonidine [44, 79, 92], ketamine [18, 32, 35], buprenorphine [71], lefoxidine [75], MgSO, [16], thiopental [46]. Only 32 of the included articles clearly mentioned the funding status, 12 of which [14, 22, 25, 27, 38, 39, 41, 43, 51, 73, 74, 77] were supported by institutional foundation, and 20 studies [17, 19-21, 30, 32-35, 40, 42, 49, 56, 61, 64, 66-68, 78, 79] declared no financial supports (Table 1).

The methodological quality of the included studies

Sixty-nine [14, 16-21, 23-37, 39-43, 45-53, 56, 58-62, 64-67, 69, 71-90, 92-95] of the 82 included trials provided a detailed description of randomization. Odd/even admission number was used in the process of randomization in one trial [54]. Fifty-seven studies [17, 18, 21, 23-26, 28-34, 37, 39-49, 51, 52, 54, 55, 57-59, 61, 62, 64, 65, 67, 69, 72, 73, 76, 77, 79, 81-90, 92, 95, 96] were double-blinded; 59 trials [16-21, 23-26, 29, 30, 32, 33, 35-37, 39-42, 44-47, 49, 52-60, 62, 64-69, 73, 76, 77, 79, 81-89, 92, 93, 95, 96] reported allocation concealment. All the studies had no incomplete outcome (attrition bias) and all the studies reported all the end points mentioned in the Methods section (reporting bias). Other bias might exist in six trials [40, 43, 66, 74, 83, 94] (the type of surgery was not clear). An overview of the risk of bias is summarized in Figure 2.

Results of meta-analysis

Dexmedetomidine vs. placebo: Forty-three trials [14-31, 35-42, 44-47, 49-61], including 2,486 patients, investigated the efficacy of preventing nausea, meanwhile vomiting was detected in 27 trails [17, 21-25, 29, 31-35, 38, 40, 43, 45, 47-52, 55, 56, 60-62] including 1,575 patients, by comparing dexmedeto-

author	Year	Particip- ants	Type of an- esthesia	Type of surgery	Trail	Dosage regimen	Comparisons	To- tal	nau- sea	vom- iting	Operation time (Mean ± SD or median, min.)	Fund- ing
Zhao [14]	2014	adults	GA	Thyroidectomy	I	S	dexmedetomidine IV 0.4 µg/kg	30	0	-	150.4±15.6	1)
							dexmedetomidine IV 0.8 µg/kg	30	0	-	152.7±15.2	
							placebo IV	30	4	-	148.5±14.6	
Yektas [15]	2014	adults	SA	inguinal surgery	I.	S	dexmedetomidine SA 2 µg	20	4	-	-	-
							dexmedetomidine SA 4 µg	20	5	-		
							placebo SA	20	2	-		
Shahi [16]	2014	adults	EA	lower limb surgery	1	S	dexmedetomidine EA 0.5 µg/kg	40	6	-	-	-
							MgSO ₄ EA 50 mg	40	3	-		
							placebo	40	4	-		
Nie [17]	2014	adults	SA	elective caesarean delivery	Е	S	dexmedetonidine IV 0.5 µg/kg	40	1	0	40.2±7.5	No
							placebo IV	38	2	0	39.2±6.7	
Gyanesh [18]	2014	children	GA	MRI examination	1	С	dexmedetomidine IV	52	2	-	18±5	-
							ketamine IV	52	5	-	18±6	
							placebo IV	46	3	-	19±6	
Dinesh [19]	2014	adults	SA	inguinal hernia repair, vaginal hyster- ectomy, arthroscopic ACL tear repair	Ι	L	dexmedetomidine IV	50	2	-	140.9±33.4	No
							placebo IV	50	0	-	137.2±33.1	
Almarakbi [20]	2014	adults	PNB	abdominal hysterectomy	1	L	dexmedetomidine PNB	25	1	-	72.6±7.5	No
							Placebo PNB	25	2	-	74.5±9.1	
Agarwal [21]	2014	adults	PNB	upper limb surgeries	1	L	dexmedetomidine PNB	25	0	0	-	No
							placebo PNB	25	0	0		
Wu [22]	2013	adults	GA	laparoscopic surgery	Е	S	dexmedetomidine IV 1.0 µg/kg	40	1	1	94.62±5.28	2
							placebo IV	40	5	4	92.16±6.36	
Tarbeeh [23]	2013	adults	SA	lower limb orthopedic surgery	1	L	dexmedetomidine SA 10 μ g	20	1	0	-	-
							fentanyl SA 25 µg	20	1	2		
							placebo SA	20	0	0		
Shin [24]	2013	adults	GA	laparoscopically assisted vaginal hysterectomy, total abdominal hyster- ectomy, ovarian surgery	Ι	S	dexmedetomidine IV 1.0 µg/kg	21	2	0	-	-
							placebo IV	21	3	0		
Mizrak [25]	2013	children	GA	adenotonsillectomy	1	S	dexmedetomidine IV 0.5 µg/kg	30	2	0	22.7±4.05	3
							placebo IV	30	3	0	24.3±5.5	
Mazanikov [26]	2013	adults	GA	endoscopic retrograde cholangiopan- creatography	I	L	dexmedetomidine IV	25	2	-	22±12	-
							placebo IV	25	1	-	25±14	
Lee [27]	2013	adults	GA	laparoscopically assisted vaginal hysterectomy	Ι	L	dexmedetomidine IV	28	1	-	-	4)
							placebo IV	29	8	-		
Kim a [29]	2013	adults	GA	uterine artery embolization	I.	С	dexmedetomidine IV 0.2 μ g/kg/h	25	8	8	43±8	-

Table 1. Characteristics of the included trials

							placebo IV	25	5	18	42±8	
Kim b [28]	2013	adults	GA	modified radical mastectomy	I.	S	dexmedetomidine IV 0.5 ug/kg	46	18	-	120	-
							placebo IV	46	26	-	118	
Gupta [30]	2013	chiildren	GA	corrective surgery	I	L	dexmedetomidine IV	18	2	-	165.3±77.7	No
							placebo IV	18	9	-	122±36.7	
Esmaoglu [31]	2013	adults	SA	transurethral endoscopic surgery	Ι	L	dexmedetomidine SA	30	2	1	58.5±21.9	-
							placebo SA	30	1	1	56.3±22.5	
Chen [32]	2013	children	GA	elective strabismus surgery	I	L	dexmedetomidine IV	27	-	4	35.8±7.3	No
							ketamine IV	27	-	12	34.6±7.5	
							placebo IV	24	-	11		
Bindu [33]	2013	adults	GA	elective general surgical, urological and gynecological surgeries	Е	S	dexmedetomidine IV 0.75 ug/kg	25	-	1	-	No
							placebo IV	25	-	2		
Ali [34]	2013	children	GA	adenotonsillectomy	Е	S	dexmedetomidine IV 0.3 ug/kg	40	-	4	36.7±10.8	No
							propofol IV 1 mg/kg	40	-	5	38.6±12.2	
							placebo IV	40	-	3	35.0±9.8	
Singh [35]	2012	adults	GA	laparoscopic surgical procedures	Е	S	dexmedetomidine IV 1 ug/kg	40	2	1	59.14±4.28	No
							placebo	40	7	4	57.86±5.68	
Jain [36]	2012	adults	SA	elective lower limb orthopaedic surgery	Ι	S	dexmedetomidine EA 2 ug/kg	30	0	-	80.9	-
							placebo EA	30	0	-	79.3	
Hong [37]	2012	adults	SA	transurethral resection of the prostate	Ι	S	dexmedetomidine IV 1.0 ug/kg	26	2	-	31.2±18.4	-
							placebo IV	25	1	-	28.2±13.3	
Wu [38]	2011	adults	GA	total hip replacement	Po	С	dexmedetomidine IV 0.2 ug/(kgh)	20	1	0	121±28	5
							placebo IV	20	6	5	116±23	
Ohtani [39]	2011	adults	GA	open gynecological abdominal surgery	Ι	С	dexmedetomidine IV	16	3	-	250±66	6
							placebo IV	16	2	-	233±69	
Gupta a [40]	2011	adults	SA	lower limb surgeries	I.	S	dexmedetomidine SA 5 ug	30	1	0	-	No
							placebo SA	30	2	0		
Cheung [41]	2011	adults	GA	bilateral third molar surgery	I.	S	dexmedetomidine IV 1 ug/kg	33	8	-	50.5±18.6	\overline{O}
							placebo IV	33	4	-	56.7±23.8	
Abdelmageed [42]	2011	adults	GA	uvulopalatopharyngoplasty	Е	L	dexmedetomidine IV	20	7	-	74±43	No
							placebo IV	19	14	-	78±49	
Sato [43]	2010	children	GA	pediatric ambulatory surgery	Ι	S	dexmedetomidine IV 0.3 ug/kg	39	-	3	49±38	8
							placebo IV	42	-	3	41±32	
Neogi [44]	2010	children	EA	elective inguinal herniotomy	I	S	dexmedetomidine EA 1 ug/kg	25	3	-	39±9.43	-
							clonidine EA 1 ug/kg	25	2	-	38±7.8	
Mizrak a [46]	2010	adults	GA	inguinal hernia, laparoscopic cholecystectomy, breast biopsy	Ι	S	dexmedetomidine IV 0.5 ug/kg	30	5	-	60±13.4	-

							thiopental IV 1 mg/kg	30	4	-	62.5±12.2	
							placebo IV	30	8	-	64.5±14.2	
Mizrak b [45]	2010	adults	IVRA	carpal tunnel release	Ι	S	dexmedetomidine IV 0.5 ug/kg	15	0	0	45±19	-
							placebo IV	15	0	0	38±17	
Elcicek [47]	2010	adults	SA	lower extremity surgery	I	L	dexmedetomidine IV	30	3	0	-	-
							placebo IV	30	2	0		
Massad [49]	2009	adults	GA	elective diagnostic laparoscopic surgeries	Ι	С	dexmedetomidine IV 0.5 ug/kg/h	42	8	5	30.5±3.1	No
							placebo IV	39	15	8	28.4±2.2	
Erdil [48]	2009	children	GA	adenoidectomy	I	S	dexmedetomidine IV 0.5 ug/kg	30	-	1	38.7±17.1	-
							fentanyl IV 2.5 ug/kg	30	-	3	36.2±16.8	
							placebo IV	30	-	1	35.8±18.3	
Turan [50]	2008	adults	GA	elective intracranial surgery	Е	S	dexmedetomidine IV 0.5 ug/kg	20	0	0	256±49	-
							placebo IV	20	0	0	251±46	
Tufanogullari [51]	2008	adults	GA	laparoscopic bariatric surgery	I	С	dexmedetomidine IV 0.8 ug/kg/h	20	9	2	111±56	9
							dexmedetomidine IV 0.4 ug/kg/h	20	6	0	107±35	
							dexmedetomidine IV 0.2 ug/kg/h	20	5	1	110±62	
							placebo IV	20	13	3	116±52	
Goksu [52]	2008	adults	LA	functional endoscopic sinus surgery	Ι	L	dexmedetomidine IV	30	5	3	-	-
							placebo IV	32	25	13		
Elvan [53]	2008	adults	GA	elective total abdominal hysterectomy	Ι	L	dexmedetomidine IV	40	2	-	78.3±19.7	-
							placebo IV	40	2	-	81.9±28.2	
Tekin [54]	2007	-	SA	lower abdominal, anorectal, or extremity surgery	Ι	L	dexmedetomidine IV	30	0	-	71.02±13.58	
							placebo IV	30	0	-	72.50±14.84	
Bakhamees [55]	2007	adults	GA	elective laparoscopic Roux-en-Y gastric bypass surgery	Ι	L	dexmedetomidine IV	40	2	0	157±29	-
							placebo IV	40	3	0	155±27	
Yildiz [56]	2006	adults	GA	elective minor surgery	I	S	dexmedetomidine IV 1 ug/kg	25	6	3	-	No
							placebo IV	25	10	9		
Ozkose [57]	2006	adults	GA	elective surgery for lumbar disc disease	Ι	L	dexmedetomidine IV	20	2	-	98.35±27.4	-
							placebo IV	20	3	-	90.8±20.2	
lsik [58]	2006	children	GA	magnetic resonance imaging examination	Ι	S	dexmedetomidine IV 1 ug/kg	21	1	-	44.4±20.9	-
							placebo IV	21	2	-	39.3±8.4	
Gurbet [59]	2006	adults	GA	total abdominal hysterectomy	I	L	dexmedetomidine IV	25	6	-	101±25	-
							placebo IV	25	15	-	109±25	
Cicek [60]	2006	adults	GA	septorhinoplasty	Ι	L	dexmedetomidine IV	25	8	4	183±37	-
							placebo IV	25	11	6	186±47	
Unlugenc [61]	2005	adults	GA	elective abdominal surgery	I	S	dexmedetomidine IV 1 ug/kg	30	2	0	-	No

							plcebo IV	30	4	0		
Guler [62]	2005	children	GA	adenotonsillectomy	Е	S	dexmedetomidine IV 0.5 ug/kg	30	-	11	35.73±8.3	-
							plcebo IV	30	-	16	37.63±5.6	
Verma [63]	2014	adults	LA	tympanoplasty	Ι	L	dexmedetomidine IV	39	4	2	44.9±5.3	-
							propofol IV	37	3	1	46.8±6.07	
Singh [64]	2014	children	GA	dental procedures	Ι	S	dexmedetomidine IV 3 ug/kg	28	-	0	-	No
							dexmedetomidine IV 4 ug/kg	28	-	0	-	
Sheta [65]	2014	children	GA	complete dental rehabilitation	Ι	S	dexmedetomidine IN 1 ug/kg	36	6	-	112.1±18.8	
							midazolam IN 0.2 mg/kg	36	5	-	107.5±20.8	
Sethi [66]	2014	adults	GA	endoscopic retrograde cholangiopancrea-tography	Ι	L	dexmedetomidine IV	30	-	2	-	No
							midazolam IV	30	-	4		
Peng [67]	2014	children	GA	cerebral angiography	Ι	L	dexmedetomidine IV	31	0	-	31.2±11.2	No
							propofol IV	31	1	-	35.8±10.7	
Manuar [68]	2014	adults	SA	arthroscopic knee surgery	Е	S	dexmedetomidine IA 100 ug	33	0	0	115.30±16.343	No
							fentanyl IA50 ug	33	0	0	111.36±14.046	
							ropivacaine IA 75 mg	33	0	0	112.27±15.211	
Kamal [69]	2014	adults	EA	major abdominal surgery	Ι	S	dexmedetomidine EA 1.5 ug/kg	30	5	3	-	-
							morphine EA 1 mg	30	10	8		
Hasanin [70]	2014	children	GA	gastrointestinal endoscopy	I	L	dexmedetomidine IV	40	-	0	20.70±10.71	-
							propofol IV	40	-	1	19.65±7.69	
Gupta [71]	2014	adults	SA	elective lower abdominal surgeries	Ι	S	dexmedetomidine SA 5 ug	30	4	-	-	-
							buprenorphine SA 60 ug	30	2	-		
El Shamaa [72]	2014	children	GA	lower abdominal and perineal surgeries	Ι	S	dexmedetomidine EA 2 ug/kg	25	1	-	61±26	-
							morphine EA 30 ug/kg	25	4	-	63±24	
Techanivate [73]	2012	-	GA	elective ambulatory gynecologic diagnostic laparoscopy	Е	S	dexmedetomidine IV 0.5 ug/kg	20	1	-	35	10
							fentanyl IV 0.5 ug/kg	20	5	-	35	
Wan [74]	2011	adults	GA	abdominal surgery, thoracic surgery, lower limb surgery, spine surgery	Po	С	dexmedetomidine IV	102	10	-	-	1
							midazolam IV	98	11	-	-	
Nasr [75]	2011	adults	GA	ultra-rapid opiate detoxification	I	С	dexmedetomidine IV	30	0	0	330±18	-
							lefoxidine OR	30	4	1	335±22	
Mountain [76]	2011	children	GA	dental restoration	I	S	dexmedetomidine OR 4 ug/kg	22	0	0	-	-
				and possible tooth extraction			midazolam OR 0.5 ug/kg	19	0	0		
Jung [77]	2011	adults	GA	elective total laparoscopic hysterectomy	Е	L	dexmedetomidine IV	25	0	0	98.3±22.5	12
							remifentanil IV	25	3	2	97.0±25.3	
Gupta b [78]	2011	adults	SA	lower abdominal surgeries	Ι	S	dexmedetomidine SA 5 ug	30	1	0	180±45	No
							fentanyl SA 25 ug	30	2	1	170±40	

Bajwa a [80]	2011	adults	EA	vaginal hysterectomies	I	S	dexmedetomidine EA 1.5 ug/kg	25	4	1	96.34±14.58	No
							clonidine EA 2 ug/kg	25	3	1	99.78±13.68	
Bajwa b [79]	2011	adults	EA	lower limb orthopedic surgery	I.	S	dexmedetomidine EA 1 ug/kg	50	7	2	102.48±12.36	-
							fentanyl EA 1 ug/kg	50	13	6	108.78±14.49	
Olutoye [81]	2010	children	GA	tonsillectomy and adenoidectomy	I	S	dexmedetomidine IV 0.75 ug/kg	26	2	0	22.0±8.4	-
							dexmedetomidine IV 1 ug/kg	27	0	0	21.3±9.7	
							morphine IV 50 ug/kg	30	0	0	22.8±7.6	
							morphine IV 100 ug/kg	26	3	2	25.9±9.5	
							placebo EA	25	1	-	39±7.6	
Turgut [82]	2009	adults	GA	supratentorial craniotomy	I	L	dexmedetomidine IV	25	3	1	216.08±52.01	-
							remifentanil IV	25	7	3	229.40±37.06	
SaLman [84]	2009	adults	GA	ambulatoty gynecologic laparoscopic surgery	Ι	L	dexmedetomidine IV	30	-	0	38±22	-
							remifentanil IV	30	-	8	35±22	
Shehabi [83]	2009	adults	GA	pump cardiac surgery	Po	С	dexmedetomidine IV (0.1-0.7) ug/ kg/h	152	21	-	-	-
							morphine IV (10-70) ug/kg/h	147	15	-		
Rutkowska [85]	2009	adults	PNB	arteriovenous fistula formation	1	L	dexmedetomidine IV	32	3	-	-	-
							midazolam IV	29	2	-		
Aksu [86]	2009	adults	GA	rhinoplasty	Е	S	dexmedetomidine IV 0.5 ug/kg	20	0	0	175.57±53.65	-
							fentanyl IV 1 ug/kg	20	0	1	179.26±64.24	
Turgut [87]	2008	adults	GA	spinal laminectomy	I	L	dexmedetomidine IV	25	8	3	84	-
							fentanyl IV	25	18	12	85	
Kaygusuz [88]	2008	adults	GA	extracorporeal shockwave lithotripsy	1	L	dexmedetomidine IV	20	2	0	37.8±9.2	
							propofol IV	20	5	2	35.5±6.0	
Karaaslan [89]	2007	adults	MAC	septoplasty or endoscopic nasal surgery	I	L	dexmedetomidine IV	35	7	-	28.67±1.27	-
							midazolam IV	35	2	-	30.67±1.33	
Demiraran [90]	2007	adults	GA	esophagogastroduodenal endoscopy	1	L	dexmedetomidine IV	25	1	0	8.9±1.3	-
							midazolam IV	25	2	2	9,03±1.2	
Bulow [91]	2007	adults	GA	gynecologic videolaparoscopic surgery	Ι	С	dexmedetomidine IV 0.5 ug/kg	15	4	-	118.7±13.4	-
							remifentanil IV 0.3 ug/kg	15	2	-	92.9±8.0	
Kanazi [92]	2006	adults	SA	transurethral resection of prostate or bladder	Ι	S	dexmedetomidine SA 3 ug	16	0	0	56±18	-
				tumor			clonidine SA 30 ug	16	0	0	77±48	
Jalowiecki [93]	2005	adults	GA	ambulatory elective colonoscopy	I	L	dexmedetomidine IV	19	5	-	-	-
							fentanyl IV	24	0	-		
Herr [94]	2003	adults	-	coronary artery bypass graft surgery	Po	L	dexmedetomidine IV	148	22	-	-	-
							propofol IV	147	19	-		
Chaves [95]	2003	adults	GA	videolaparoscopic cholecystectomy	I.	L	dexmedetomidine IV	21	9	-	-	-

remifentanil IV 21 6

GA: general anesthesia, SA: spinal anesthesia, EA: epidural anesthesia, PNB: peripheral neural blockade, IVRA: intravenous regional anesthesia, MAC: monitored anesthesia care, IV: intravenous, IA: intravenicular, OR: oral, IN: intravenasal, I: induction of anesthesia, E: end of surgery, Po: postoperative, S: single dose, L: loading dose followed by continuous infusion, C: continuous infusion, O: National Natural Science Foundation of China (81000824). @ Science and Technology Program of Guangdong Province, Research Project of Commission on Innovation and Technology of Guangzhou (2011KP304), Youth Foundation of The Third Affiliated Hospital of Guangzhou Medical University (2010Y05). @ Supported by themselves and institution. @ Supported by Wonkwang University. @ Medical and Health Foundation of Guangzhou City (201102A213071). @ Supported in part by a Granti-n-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan to N.O. (No. 21791429) and E.M. (No. 22659362). @ Supported in part by the University of Hong Kong CRCG Small Project Fund (200807176008). @ Supported in part by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Science, Sports, and Culture (No. 17591627). @ Supported in part by an unrestricted educational grant from Hospira, Inc. (Lake Forest, IL), endowment funds from the Margaret Milam McDermott Distinguished Chair in Anesthesiology, and the White Mountain Institute, a non-profit private foundation (Paul F. White, President). @ Rachadapisek Sompoch Fund of Chulalongkorn University, Bangkok, Thailand (RA 57/53). @ National Natural Science Foundation of China (81060033). @ 2010 Research Institute of Medical Science, St Vincent's Hospital, Suvon, Resublic of Korea.

Comparison	Number	dexme-	placebo	RR (95% CI)	1 ²	References
	of studies	detomidine				
Nausea						
Investigator initiated trail/dosage regimen/dose						
Induce	26	101/783	172/776	0.59 (0.48, 0.73)	20%	[14, 18, 19, 24-30, 37, 39, 41, 46, 47, 49, 51-55, 57-61]
End	5	11/160	28/157	0.38 (0.21, 0.69)	0%	[17, 22, 35, 42, 50]
Single dose	15	50/447	79/444	0.63 (0.47, 0.86)	0%	[14, 17, 20, 22, 24, 25, 28, 35, 37, 41, 45, 46, 50, 56, 58, 61]
Loading dose followed by continuous infusion	13	42/381	93/383	0.46 (0.34 0.62)	24%	[19, 26, 27, 30, 42, 47, 52-55, 57, 59, 60]
0.5 μg/kg	6	26/181	39/179	0.67 (0.45, 0.99)	0%	[17, 25, 28, 45, 46, 50]
1.0 µg/kg	8	24/236	36/235	0.67 (0.41, 1.07)	5%	[22, 24, 35, 37, 41, 56, 58, 61]
Vomiting						
Investigator initiated trails/dosage regimen/dose						
Induce	13	29/389	63/388	0.45 (0.31, 0.67)	0%	[24, 25, 29, 32, 43, 47-49, 51, 52, 55, 60, 61]
End	7	18/235	29/233	0.62 (0.38, 1.02)	0%	[17, 22, 33-35, 50, 62]
single dose	14	25/425	42/426	0.60 (0.39, 0.92)	0%	[17, 22, 24, 25, 33-35, 43, 45, 48, 50, 56, 61, 62]
loading dose followed by continuous infusion	5	11/152	30/151	0.36 (0.19, 0.67)	0%	[32, 47, 52, 55, 60]
0.5 µg/kg	6	12/165	17/163	0.71 (0.40, 1.25)	0%	[17, 25, 45, 48, 50, 62]
1.0 µg/kg	5	5/156	17/156	0.29 (0.12, 0.75)	0%	[22, 24, 35, 56, 61]

Table 2. Efficacy of intravenous dexmedetomidine on reducing nausea and vomiting compared with placebo

Table 3. Efficacy of dexmedetomidine on reducing nausea and vomiting with high risk factors compared with placebo

Comparison	Number of studies	dexmedetomidine	placebo	RR (95% CI)	²	References
Nausea						
Female sex	11	51/348	85/344	0.59 (0.44, 0.79)	0%	[17, 20, 22, 24, 27-29, 39, 49, 53, 59]
Laparoscopy	6	19/220	46/218	0.40 (0.25, 0.66)	0%	[22, 27, 35, 46, 49, 55]
Postoperative opioid treatment	9	40/233	79/233	0.50 (0.37, 0.69)	22%	[27, 29, 38, 42, 51, 55, 59-61]
Vomiting						
Female sex	5	14/168	30/163	0.30 (0.13, 0.66)	0%	[17, 22, 24, 29, 49]
Laparoscopy	5	8/182	19/179	0.36 (0.15, 0.87)	0%	[22, 35, 49, 51, 55]
Postoperative opioid treatment	7	14/185	34/185	0.42 (0.25, 0.70)	0%	[29, 33, 38, 51, 55, 60, 61]

		blas)					Herr 2003	•	•	?	٠	•	?
	(s	ction					Hong 2012	٠	٠	۲	٠	•	٠
	on bia	d dete	~				Isik 2006	•	٠	٠	٠	٠	٠
	electio	as an	bias	n bias	(s		Jain 2012	•		۲	٠	•	•
	ion (s	ice bi	lection	attritio	g bla		Jalowiecki 2005	•	?	٠	٠	•	٠
	nerat	ormar	nt (se	lata (portin		Jung 2011	•	•	٠	٠	•	٠
	ice ge	(perf	alme	ome	ng (re		Kamal 2014	•	•	۲	٠	•	٠
	equer	ethod	conce	e outo	pode.		Kanazi 2006	•	۲	۲	٠	•	٠
	dom s	m Bull	ation	mplet	ctive r	r bias	Karaaslan 2007	•	•	٠	۲	•	٠
	Ranc	Blind	Alloc	Incor	Sele	Othe	Kaygusuz 2008	•	٠	٠	٠	•	٠
Abdelmageed 2011	•	•	٠	•	•	•	Kim a 2013	•	•	٠	۲	•	٠
Agarwal 2014	•	•	٠	٠	•	٠	Kim b 2013	•	•	?	•	•	•
Aksu 2009	•	•	٠	•	•	•	Lee 2013	•	•	?	٠	٠	٠
Ali 2013	•	•	?	۲	•	•	Lin 2009	•	٠	٠	•	•	•
Almarakbi 2014	•	?	٠	٠	•	٠	Manuar 2014	?	?	٠	•	•	٠
Bajwa a 2011	?	?	?	٠	•	•	Massad 2009	٠	•	•	•	•	•
Bajwa b 2011	•	۲	٠	٠	•	•	Mazanikov 2013	•	٠	۲	•	•	•
Bakhamees 2007	?	•	۲	٠	۲	•	Mizrak 2013	•	•	٠	٠	•	٠
Bindu 2013	•	٠	٠	٠	۲	•	Mizrak a 2010	•	•	٠	•	•	•
Bulow 2007	?	?	?	۲	•	•	Mizrak b 2010	•	•	٠	•	•	٠
Chaves 2003	٠	٠	٠	٠	•	•	Mountain 2011	•	•	٠	•	•	٠
Chen 2013	٠	•	٠	•	•	٠	Nasr 2011	•	?	?	•	•	٠
Cheung 2011	•	•	•	•	•	•	Neogi 2010	?	•	•	•	•	•
Cicek 2006	•	•	٠	۲	•	•	Nie 2014	•	•	۲	•	•	٠
Demiraran 2007	•	•	?	٠	•	٠	Ohtani 2011	•	•	٠	•	٠	٠
Dinesh 2014	•	?	•	•	•	•	Olutoye 2010	•	•	٠	•	•	•
Elcicek 2010	٠	•	٠	۲	۲	٠	Ozkose 2006	?	•	٠	•	•	•
El Shamaa 2014	•	•	?	٠	•	•	Peng 2014	•	•	٠	٠	•	٠
Elvan 2008	٠	•	۲	٠	٠	•	Rutkowska 2009	•	•	٠	•	•	•
Erdil 2009	•	•	?	٠	۲	•	Salman 2009	•	•	•	•	•	•
Esmaoglu 2013	•	•	?	٠	•	٠	Sato 2010	•	•	?	٠	٠	?
Goksu 2008	۲	٠	٠	٠	•	٠	Sethi 2014	•	•	٠	•	•	?
Guler 2005	٠	•	٠	٠	•	•	Shahi 2014	•	?	٠	•	•	•
Gupta 2013	•	•	•	•	•	•	Shehabi 2009	•	٠	٠	•	•	?
Gupta 2014	•	?	?	۲	•	٠	Sheta 2014	٠	٠	۲	•	٠	•
Gupta a 2011	•	•	•	•	•	?	Shin 2013	•	•	•	•	•	•
Gupta b 2011	?	•	•	٠	٠	٠	Singh 2012	•	?	٠	•	•	•
Gurbet 2006	۲	•	۲	۲	٠	٠	Singh 2014	•	•	٠	•	•	۲
Gyanesh 2014	٠	•	۲	٠	٠	•	Tarbeeh 2013	•	•	٠	•	•	•
Hasanin 2014	?	?	?	٠	٠	٠	Techanivate 2012	•	٠	۲	٠	•	٠





Figure 2. Summary of the risk of bias of the included studies.

midine with placebo. The incidence of nausea (pooled RR = 0.61, 95% CI: 0.50 to 0.73) and vomiting (pooled RR = 0.48, 95% CI: 0.36 to 0.64) in the dexmedetomidine group was significantly lower than the placebo group (**Figures 3**, **4**). Begg's Test suggested that no significant publication bias existed in the comparisons of nausea (P = 0.957) and vomiting (P = 0.488) between dexmedetomidine and placebo.

Further, factors that affected nausea and vomiting were evaluated through subgroup analysis.

Type of anesthesia: Dexmedetomidine significantly reduced the incidence of both nausea (pooled RR of 27 trails [14, 18, 22, 24-30, 35, 38, 39, 41, 42, 46, 49-51, 53, 55-61]: 0.57, 95% Cl: 0.46 to 0.69) and vomiting (pooled RR of 20 trails [21, 22, 24, 25, 29, 32-35, 38, 43, 48-51, 55, 56, 60-62]: 0.50, 95% Cl: 0.37 to 0.68) after general anesthesia, but not regional anesthesia (nausea: pooled RR of 16 trials [15-17, 19-21, 23, 31, 36, 37, 40, 44, 45, 47, 52, 54]: 0.78, 95% Cl: 0.51 to 1.19; vomiting: pooled RR of seven trails [17, 23, 31, 40, 45, 47, 52]: 0.30, 95% Cl: 0.11 to 0.85) (**Figures 3, 4**).

Route of administration: Dexmedetomidine injected intravenously lowered the incidence of nausea (pooled RR of 34 trails [14, 17-19, 22, 24-30, 35, 37-39, 41, 42, 45-47, 49-61]: 0.55, 95% CI: 0.45 to 0.67) and vomiting (pooled RR of 23 trails [17, 22, 24, 25, 29, 32-35, 38, 43, 45, 47-52, 55, 56, 60-62]: 0.47, 95% CI: 0.35 to 0.63), but not epidurally (nausea: pooled RR of three trails [16, 32, 36, 44]: 1.80, 95% CI: 0.64 to 5.07; vomiting: none) or intrathecally (nausea: pooled RR of four trials [15, 23, 31, 40]: 1.73, 95% CI: 0.63 to 4.71; vomiting: pooled RR of three trails [23, 31, 40]: 1.00, 95% CI: 0.07 to 15.26) (Figures 5, 6).

Administration of IV dexmedetomidine: Subgroup analysis not only demonstrated single dose (nausea: pooled RR of 15 trails [14, 17, 20, 22, 24, 25, 28, 35, 37, 41, 45, 46, 50, 56, 58, 61]: 0.63, 95% CI: 0.47 to 0.86; vomiting: pooled RR of 14 trails [24, 25, 29, 32, 43, 47-49, 51, 52, 55, 60, 61]: 0.60, 95% CI: 0.39 to 0.92), loading dose followed by continuous infusion (nausea: pooled RR of 13 trails [19, 26, 27, 30, 42, 47, 52-55, 57, 59, 60]: 0.46, 95% CI: 0.34 to 0.62; vomiting: pooled RR of five trails [32, 47, 52, 55, 60]: 0.36, 95% CI: 0.19 to 0.67) of dexmedetomidine could reduce the incidence of nausea and vomiting with any investigator initiated trails, induce of anesthesia (nausea: pooled RR of 26 trails [14, 17, 20, 22, 24, 25, 28, 35, 37, 41, 45, 46, 50, 56, 58, 61]: 0.59, 95% CI: 0.48 to 0.73; vomiting: pooled RR of 13 trails [24, 25, 29, 32, 43, 47-49, 51, 52, 55, 60, 61]: 0.45, 95% CI: 0.31 to 0.67) and end of surgery (nausea: pooled RR of five trails [17, 22, 35, 42, 50]: 0.38, 95% CI: 0.21 to 0.69; vomiting: pooled RR of seven trails [17, 22, 33-35, 50, 62]: 0.62, 95% CI: 0.38 to 1.02), but also suggested a beneficial effect of a single-dose bolus of 0.5 µg/kg dexmedetomidine compared with placebo on nausea (pooled RR of six trials [17, 25, 28, 45, 46, 50]: 0.46, 95% CI: 0.34 to 0.62), while 1.0 µg/ kg dexmedetomidine reduced the incidence of vomiting (pooled RR of five trials [22, 24, 35, 56, 61]: 0.29, 95% CI: 0.12 to 0.75) (Table 2).

Efficacy on PONV with high risk factors: Subgroup analysis suggested a significant efficacy of dexmedetomidine on nausea and vomiting with high risk factors, like female sex (nausea: pooled RR of 11 trials [17, 20, 22, 24, 27-29, 39, 49, 53, 59]: 0.59, 95% CI: 0.44 to 0.79; vomiting: pooled RR of five trials [17, 22,

Study cove Events Total Events Total Weight M.H. Excel, 95%, Cl 1.21 General ansethesia Abdeimaged 2011 7 20 14 19 6.3% 0.47 (0.25, 0.91) Bakhamees 2007 2 40 3 41 17% 2.00 (0.67, 6.00) Cheung 2011 8 33 4 33 1.7% 2.00 (0.67, 6.00) Cheung 2006 2 40 2 40 0.9% 1.00 (0.15, 6.76) Gyneeh 2014 2 52 18 9.0% 0.20 (0.16, 0.68)		Dexmedeton	nidine	Placel	00		Risk Ratio	Risk Ratio
1.2.1 General anesthesia Bakhamese 2007 2 40 3 40 1.3% 0.47 (0.25, 0.91) Bakhamese 2007 2 40 3 40 1.3% 0.67 (0.12, 3.78) Cleek 2006 8 25 1 25 48% 0.73 (0.35, 1.50) Cleek 2006 6 25 15 25 6.5% 0.40 (0.15, 0.60) Gupta 2013 2 18 9 18 9.9% 0.22 (0.60, 0.69) Gupta 2014 2 52 5 5 0.40 (0.15, 0.60) 1 Kim a 2013 8 25 5 25 0.5% (0.60) (0.61, 4.22) 1 Massad 2009 8 42 15 9 6.5% (0.50) (0.23, 10.61) 1 Marak 2010 5 36 83 3.5% (0.63) (0.24, 10.61) 1	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H. Fixed, 95% Cl
Abdelmaged 2011 7 20 14 19 6.3% 0.47 (0.25, 0.91) Bakhamese 2007 2 40 3 40 1.3% 0.47 (0.25, 0.91) Cheung 2011 8 33 4 33 1.7% 2.00 (0.67, 6.00) Cheung 2011 2 12 440 7 40 0.9% 1.00 (0.75, 6.76) Gunder 2006 2 40 2 40 0.9% 1.00 (0.15, 6.76) Gunder 2006 6 25 15 25 6.5% 0.40 (0.19, 0.66) Gunder 2006 1 221 2 24 6 1.4% 0.59 (0.10, 3.8) Gunder 2006 1 221 2 24 6 1.4% 0.59 (0.10, 3.8) Gunder 2006 1 221 2 24 6 1.4% 0.59 (0.10, 3.8) Gunder 2006 1 221 2 24 6 1.4% 0.59 (0.10, 3.8) Hisk 2006 1 221 2 25 2 3.46 1.4% 0.59 (0.10, 3.8) Hisk 2006 1 221 2 25 2 3.46 1.4% 0.59 (0.10, 3.8) Hisk 2006 1 221 2 25 0.4% 0.59 (0.24, 1.04) Mazanikov 2013 2 25 1 25 0.4% 0.53 (0.24, 1.04) Mazanikov 2013 2 25 1 25 0.4% 0.53 (0.24, 1.04) Mazanikov 2013 2 25 1 25 0.4% 0.53 (0.23, 7.81) Cyckose 2006 2 2 02 3 20 1.3% 0.67 (0.12, 3.71) Mirznk 2013 1 6 2 16 0.9% 1.50 (0.23, 7.81) Cyckose 2006 2 2 0.3 3 0 1.3% 0.67 (0.12, 3.71) Mirznk 2013 2 21 3 20 1.3% 0.67 (0.12, 3.71) Mirznk 2013 2 21 3 20 1.3% 0.67 (0.12, 3.71) Mirznk 2013 2 21 3 20 1.3% 0.67 (0.12, 3.71) Mirznk 2013 2 21 3 20 1.3% 0.67 (0.12, 3.71) Mirznk 2013 2 21 3 20 1.3% 0.67 (0.12, 3.71) Mirznk 2013 2 21 3 20 1.3% 0.67 (0.12, 3.57) Shin 2013 2 21 3 20 1.3% 0.67 (0.12, 3.57) Shin 2013 2 21 3 20 1.3% 0.67 (0.12, 3.59) Shin 2013 2 21 3 20 1.3% 0.67 (0.12, 3.57) Tufanogulari 2008 5 20 13 20 5.7% 0.38 (0.10, 2.53) Wu 2011 1 20 6 20 2.6% 0.50 (0.26) 0.77 (0.20, 1.64) Unlugenc 2005 2 3 0 4 30 1.7% 0.50 (0.25, 5.17) Dist 2014 0 30 4 30 2.0% 0.11 (0.1, 1.98) Mirznk 2010 1 3 30 2 30 0.9% 0.50 (0.55, 5.17) Dist 2014 1 25 0 25 0.0% 0.50 (0.25, 0.164) Hores 2014 0 30 0 30 With estimable Mirznk 2010 1 3 30 2 20 0.9% 0.50 (0.05, 5.17) Dist 2014 1 4 40 2 38 0.9% 0.47 (0.45, 0.33) Mirznk 2010 1 5 0 15 Not estimable Mirznk 2	1.2.1 General anesthe	sia				-		
Bakhamese 2007 2 40 3 40 13% 0.67 [0.12, 3.78] Cloek 2006 8 25 11 25 4.8% 0.73 [0.35, 150] Elvan 2006 2 40 2 40 2 40 0.9% 0.22 [0.66, 0.89] Gupta 2013 2 18 9 18 39% 0.22 [0.66, 0.89] Gupta 2014 2 52 3 46 1.4% 0.59 [0.10, 3.38] Isk 2006 1 21 2 2 10 9% 0.40 [0.19, 0.68] Gyanesh 2014 2 52 3 46 113% 0.69 [0.45, 108] His 2013 18 45 25 5 25 2.2% 1.69 [0.61, 4.22] His 2013 18 45 25 5 125 2.4% 0.50 [0.61, 1.42] Haxakov 2013 2 25 1 25 0.4% 0.50 [0.65, 108] Mizrak 2013 1 28 8 29 3.4% 0.51 [0.24, 77] Mizrak 2013 2 25 1 25 0.4% 2.00 [0.19, 20.67] Mizrak 2013 2 25 1 25 0.4% 2.00 [0.19, 20.67] Mizrak 2013 2 25 1 25 0.4% 0.50 [0.24, 104] Mizrak 2010 5 30 8 30 3.5% 0.63 [0.24, 104] Mizrak 2010 5 30 8 30 3.5% 0.63 [0.24, 104] Mizrak 2010 5 30 8 30 3.5% 0.63 [0.24, 104] Mizrak 2010 5 30 8 30 3.5% 0.63 [0.24, 104] Mizrak 2010 5 30 8 30 3.5% 0.63 [0.23, 156] Othan 2011 3 10 2.25 1 Turah 2008 0 2 20 3 20 13% 0.67 [0.12, 357] Sing 2012 2 40 7 40 3.0% 0.23 [0.17, 102, 37] Turah 2008 0 2 20 3 20 57% Not estimable Mizrak 2013 1 2.6 20 2.26% 0.17 [0.2, 128] Unhugenc 2005 2 230 4 30 1.7% 0.63 [0.17, 0.8] Turah 2013 1 40 5 40 2.2% 0.28 [0.17, 0.8] Turah 2013 1 2.6 2.0 2.5% Not estimable Anamakb 2014 1 25 0 25 0.57 Not estimable Anamakb 2014 1 2.5 0 25 0.57 Not estimable Anamakb 2014 1 2.5 0 25 0.57 Not estimable Anamakb 2014 1 2.5 0 2.5 0.025, 5.17] Total events 106 72 177 8 1.6% 0.57 [0.46, 6.69] Mizrak 2013 3 0 2.30 0.9% 0.50 [0.27, 6.34] Falser overall effect 2 = 5.4 (P < 0.00001) 1.2.2 Regional anesthesia Anamakb 2014 1 2.5 0 2.5 0.05% 0.17 [0.02, 1.8] Mizrak 2013 2 30 0.9% 0.47 [0.04, 5.03] Mizrak 2014 1 40 2 30 0.9% 0.47 [0.04, 5.03] Mizrak 2014 1 40 2 23 0.09% 0.47 [0.04, 5.03] Mizrak 2014 1 40 2 23 0.09% 0.47 [0.04, 5.03] Mizrak 2014 1 40 2 23 0.09% 0.47 [0.04, 5.03] Mizrak 2014 1 40 2 23 0.09% 0.47 [0.04, 5.03] Mizrak 2014 1 40 2 23 0.09% 0.47 [0.04, 5.03] Mizrak 2014 1 40 2 20 0 20 0.2% 0.00 [0.3, 6.6, 5] Mizrak 2014 5 20 0 20 0.2% 0.00 [0.3, 6.6, 5] Mizrak 2014 5 20 0 20 0.2% 0.00 [0	Abdelmageed 2011	7	20	14	19	6.3%	0.47 [0.25, 0.91]	
Cheurg 2011 8 33 4 33 1,7% 2.00 [0.67, 6.00] Cevel 2006 8 25 11 25 4.8% 0.73 [0.35, 15.0] Gurber 2006 6 25 15 25 6.5% 0.40 [0.19, 0.66] Gyanesh 2014 2 52 34 6 1.4% 0.59 [0.10, 3.8] Gurber 2006 1 21 2 21 0.9% 0.59 [0.05, 5.10] Kim a 2013 8 25 5 25 25 25 0.6% 0.40 [0.19, 0.66] Gyanesh 2013 18 46 28 46 1.3% 0.69 [0.45, 1.08] Lee 2013 18 46 28 46 1.3% 0.69 [0.45, 1.08] Lee 2013 18 46 28 46 0.30 0.13 [0.02, 0.7] Massad 2009 8 42 15 39 6.8% 0.50 [0.24, 1.04] Mazanko 2013 2 25 1 25 0.4% 0.53 [0.12, 3.71] Mizrak 2013 2 26 1 25 0.4% 0.58 [0.12, 3.71] Mizrak 2013 2 20 1 3% 0.67 [0.12, 3.71] Mizrak 2013 1 8 46 2 16 0.9% 1.50 [0.23, 7.81] Cockee 2003 2 20 1 3% 0.67 [0.12, 3.71] Mizrak 2013 2 20 1 3% 0.67 [0.12, 3.71] Mizrak 2013 2 21 3 22 1.3% 0.67 [0.12, 3.71] Mizrak 2013 2 21 3 22 1.3% 0.67 [0.12, 3.71] Tufanogulari 2008 5 20 1 3 20 5.7% 0.38 [0.10, 2.53] Shin 2013 2 21 3 20 1.3% 0.67 [0.12, 3.71] Tufanogulari 2008 5 20 13 20 5.7% 0.38 [0.10, 2.53] Wu 2011 1 20 6 20 2.0 Wo testimable Unlugenc 2005 2 30 4 30 1.7% 0.50 [0.10, 2.53] Wu 2011 1 20 6 (20 2.6% 0.071 [0.22, 7.84] Tufanogulari 2008 5 20 125 4.4% 0.68 [0.26, 1.13] Mizrak 2014 0 30 4 30 2.0% 0.17 [0.02, 1.64] Wu 2011 1 20 6 (20 2.6% 0.0001) 1.2.2 Regional anesthesia Agraval 2014 0 30 4 30 2.0% 0.110 0.5, 5.17] Dineh 2014 1 25 0 25 0.0% 0.50 [0.05, 5.17] Dineh 2014 1 25 0 25 0.0% 0.50 [0.05, 5.17] Dineh 2014 1 20 0 20 0.0% 1.50 [0.27, 3.4] Enancyli 2012 2 26 1 25 0.4% 1.92 [0.10, 1.64, 6.69] Mizrak 2010 3 30 2 30 0.9% 0.50 [0.05, 5.17] Dineh 2014 1 20 0 20 0.2% 0.50 [0.27, 6.34] Heterogenetiy, Chi ² = 4.367, df = 37 (P = 0.52); F = 1.5% Test for overall effect. Z = 5.49 (P < 0.0001) Total events 138 228 Heterogenetiy, Chi ² = 4.37, df = 37 (P = 0.21); F = 1.5% Test for overall effect. Z = 5.17 (P = 0.21); F = 1.5% Test for overall effect. Z = 5.17 (P = 0.21); F = 1.5% Test for overall effect. Z = 5.17 (P = 0.02); F = 1.5% Test for overall effect. Z = 5.17 (P = 0.02); F = 1.5% Test for overall effect. Z = 5.17 (P = 0.02	Bakhamees 2007	2	40	3	40	1.3%	0.67 [0.12, 3.78]	
Clock 2006 8 25 11 25 4.8% 0.73 [0.35, 1.50] Cupta 2008 2 40 2 40 24 0 0.9% 1.00 [1.5, 6.76] Cupta 2013 2 18 9 18 3.9% 0.20 [0.6, 0.89] Cupta 2014 2 52 3 46 1.4% 0.59 [0.10, 3.8] Example 2014 2 52 3 46 1.4% 0.59 [0.10, 3.8] Example 2013 8 25 5 25 2.2% 1.60 [0.6, 1.422] Kim 2 2013 8 25 5 25 2.2% 1.60 [0.6, 1.422] Massad 2008 8 42 15 39 6.8% 0.50 [0.24, 1.04] Massad 2008 8 42 15 39 6.8% 0.50 [0.24, 1.04] Mazak 2013 2 25 1 25 0.4% 0.05 [0.26, 7.61] Marak 2013 2 25 1 25 0.4% 0.50 [0.26, 7.61] Marak 2010 5 30 8 30 3.5% 0.63 [0.23, 1.69] Marak 2013 2 25 1 25 0.4% 2.00 [0.19, 20.67] Marak 2013 2 25 1 25 0.4% 2.00 [0.19, 20.67] Marak 2013 2 25 1 20 5 0.4% 2.00 [0.19, 20.67] Marak 2010 5 30 8 30 3.5% 0.63 [0.23, 1.69] Marak 2010 5 30 8 30 3.5% 0.63 [0.23, 1.69] Marak 2010 5 30 8 30 3.5% 0.63 [0.23, 1.69] Marak 2010 5 30 8 30 3.5% 0.63 [0.23, 1.69] Marak 2013 2 21 3 20 1.3% 0.67 [0.12, 3.67] Marak 2013 2 20 3 20 1.3% 0.67 [0.12, 3.67] Marak 2013 2 2 20 0 20 Not estimable Nutagenci 205 2 20 1 20 0.5% 0.28 [0.6, 1.29] Murak 2013 1 40 5 40 22% 0.20 [0.06, 1.29] Murak 2013 1 40 5 40 22% 0.20 [0.06, 1.29] Murak 2013 1 40 5 40 22% 0.20 [0.06, 1.28] Murak 2014 1 25 2 25 0.9% 0.057 [0.46, 0.69] Murak 2013 1 40 5 40 22% 0.20 [0.02, 1.64] Murak 2014 1 25 2 25 0.9% 0.57 [0.46, 0.69] Murak 2013 1 3 0.4% 0.57 [0.46, 0.69] Murak 2014 1 25 2 25 0.9% 0.50 [0.25, 1.18] Murak 2014 1 25 2 25 0.9% 0.50 [0.25, 1.18] Marak 2014 1 20 2 0 0.5% 0.21 [0.09, 0.48] Marak 2014 1 20 2 0 0.5% 0.21 [0.09, 0.48] Marak 2014 1 20 2 0 0.5% 0.21 [0.09, 0.48] Marak 2014 1 40 2 38 0.9% 0.47 [0.24, 5.32] Murak 2014 1 40 2 38 0.9% 0.47 [0.24, 5.32] Murak 2014 1 40 2 30 0.9% 0.47 [0.24, 5.32] Marak 2014 1 40 2 30 0.9% 0.47 [0.24, 5.32] Marak 2014 1 40 2 30 0.9% 0.47 [0.24, 5.32] Marak 2014 1 40 2 30 0.9% 0.47 [0.24, 5.32] Marak 2014 1 40 2 30 0.9% 0.47 [0.24, 5.32] Marak 2014 1 40 2 30 0.9% 0.47 [0.24, 5.32] Marak 2014 1 40 2 30 0.9% 0.47 [0.24, 5.32] Marak 2014 1 40 0 2 30 0.9% 0.47 [0.24, 5.32] Marak 2014 1 40 0 2 0	Cheung 2011	8	33	4	33	1.7%	2.00 [0.67, 6.00]	
Elvan 2008 2 40 2 40 0 9.% 1.00 (0.15, 5.76) Gurbe 2013 2 18 9 18 3.9% 0.22 (0.6.0.89) Gurbe 2006 6 25 15 25 6.5% 0.40 (0.19, 0.68) Gyaneb 2014 2 52 3 46 1.4% 0.59 (0.10, 3.88) Isk 2006 1 21 2 2 1 0.9% 0.50 (0.05, 5.10) Haxanicov 2013 18 46 26 46 11.3% 0.69 (0.45, 1.08) Lee 2013 18 46 26 46 11.3% 0.69 (0.45, 1.08) Mazanicov 2013 2 25 1 25 0.4% 0.30 (0.20, 97) Mazanicov 2013 2 25 1 25 0.4% 0.20 (0.70, 2.3.71) Mazanicov 2013 2 25 1 25 0.4% 0.50 (0.25, 1.08) Mazanicov 2016 2 20 3 20 1.3% 0.67 (0.12, 3.71) Mazanicov 2016 2 20 3 20 1.3% 0.67 (0.12, 3.71) Mazanicov 2016 2 20 3 20 1.3% 0.67 (0.12, 3.78] Ontani 2011 3 16 2 16 0.9% 1.50 (0.27, 713) Mazanicov 2016 2 20 3 20 1.3% 0.67 (0.12, 3.57] Catcose 2006 2 2 0.0 20 Not estimable Muzanicov 2016 2 0 0 20 Not estimable Muzanicov 2016 2 30 4 30 1.7% 0.50 (0.10, 2.33) Muzanicov 2016 2 20 0 20 Not estimable Muzanicov 2016 2 20 0 20 Not estimable Muzanicov 2016 2 30 4 30 1.7% 0.50 (0.10, 2.33) Muzanicov 2016 2 30 4 30 1.7% 0.50 (0.10, 2.33) Muzanicov 2016 2 30 4 30 1.7% 0.50 (0.10, 2.33) Muzanicov 2016 2 30 4 30 1.7% 0.50 (0.10, 2.33) Muzanicov 2016 2 30 4 30 1.7% 0.50 (0.10, 2.33) Muzanicov 2016 2 30 4 30 1.7% 0.50 (0.10, 2.33) Muzanicov 2016 2 30 4 30 1.7% 0.50 (0.10, 2.33) Muzanicov 2016 2 30 4 30 1.7% 0.50 (0.10, 2.33) Muzanicov 2016 2 30 4 30 2.0% 0.57 (0.46, 0.69] Muzanicov 2016 1 25 0 25 Not estimable Muzanicov 2016 1 25 0 25 Not estimable Muzanicov 2016 1 25 0 25 Not estimable Muzanicov 2017 1 20 30 0.9% 0.50 (0.55, 5.77) Dinesh 2014 0 25 0 25 Not estimable Muzanicov 2014 0 30 4 30 2.00% 0.50 (0.55, 5.77) Dinesh 2014 1 2 50 0 25 0.02% 0.50 (0.55, 5.77) Dinesh 2014 1 2 50 0 20 Not estimable Muzanicov 2016 1 5 Not estimable Muzanicov 2016 1 5 0 0.2% 0.50 (0.55, 5.77) Dinesh 2014 1 2 50 0 20 0.0% 0.50 (0.55, 5.77) Dinesh 2014 1 2 50 0 20 0.0% 0.50 (0.55, 5.77) Dinesh 2014 1 2 50 0 20 0.0% 0.50 (0.55, 5.77) Dinesh 2014 1 2 50 0 20 0.0% 0.50 (0.55, 5.77) Dinesh 2014 1 2 50 0 20 0.0% 0.50 (0.55, 5.77) Dinesh 2014 1 2 50 0 20 0.	Cicek 2006	8	25	11	25	4.8%	0.73 [0.35, 1.50]	
Cupta 2006 6 25 15 25 0.60 0.89 Cyanes 2014 2 52 3 46 1.4% 0.59 0.05 0.51 Sik 2006 1 21 2 21 0.99 0.55 0.05 5.10 Kim a 2013 18 26 25 2.2% 1.80 0.61 4.22 Kim a 2013 18 46 2.6 46 11.3% 0.65 0.63 1.03 Lee 2013 1 28 8 29 4.5% 0.50 0.21 1.05 Marak 2010 5 30 8 30 3.5% 0.67 0.12 3.19 Ortanz 200 2 20 3 1.3% 0.67 0.12 3.19 Ortanz 200 2 13 20 1.3% 0.67 0.23 0.67 1.12 3.19 Turan 2008 0 20 2.5% 0.20 0.26 0.17 0.25 </td <td>Elvan 2008</td> <td>2</td> <td>40</td> <td>2</td> <td>40</td> <td>0.9%</td> <td>1.00 [0.15, 6.76]</td> <td></td>	Elvan 2008	2	40	2	40	0.9%	1.00 [0.15, 6.76]	
Curbet 2006 6 25 15 25 6.5% 0.40 [0.19, 0.66] Cyaneb 2014 2 25 3 46 1.4% 0.59 [0.10, 3.86] Isk 2006 1 21 2 21 0.9% 0.50 [0.05, 5.10] Kim a 2013 18 46 26 46 11.3% 0.69 [0.45, 1.08] Lee 2013 1 28 29 3.4% 0.13 [0.02, 0.97] Masad 2000 8 42 15 39 6.8% 0.50 [0.24, 1.04] Marankov 2013 2 25 1.5% [0.57, 0.68] 0.67 [0.12, 3.71] Mitrak 2013 2 20 31 0.67 [0.12, 3.57] Otham 2011 3 16 2 16 0.95% 1.50 [0.27, 7.68] Sing 2013 2 2 1.3% 0.67 [0.12, 3.57] 1.3% Unagenz 2006 2 20 1.5% 0.57 [0.02, 1.64] 1.5% Unagenz 2005 2 30 30 35% 0.57 [0.02, 1.64] 1.5% Unagenz 2014 0 250 25 Not estimab	Gupta 2013	2	18	9	18	3.9%	0.22 [0.06, 0.89]	
$ \begin{aligned} \begin{aligned} & \text{Cyanesh 2014} & 2 & 52 & 3 & 46 & 1.4\% & 0.59 [0.10, 3.38] \\ & \text{Isk 2006} & 1 & 21 & 2 & 21 & 0.9\% & 0.50 [0.05, 5.10] \\ & \text{Kim a 2013} & 8 & 25 & 5 & 25 & 2.2\% & 1.60 [0.61, 4.22] \\ & \text{Massad 2003} & 8 & 42 & 15 & 39 & 6.8\% & 0.50 [0.24, 1.04] \\ & \text{Massad 2003} & 8 & 42 & 15 & 39 & 6.8\% & 0.50 [0.24, 1.04] \\ & \text{Massad 2013} & 2 & 25 & 1 & 25 & 0.4\% & 2.00 [0.19, 2.067] \\ & \text{Marak 2010} & 5 & 30 & 8 & 30 & 1.3\% & 0.67 [0.12, 3.71] \\ & \text{Marak 2010} & 5 & 30 & 8 & 30 & 1.3\% & 0.67 [0.12, 3.57] \\ & \text{Marak 2010} & 5 & 30 & 8 & 30 & 1.3\% & 0.67 [0.12, 3.57] \\ & \text{Marak 2010} & 5 & 30 & 8 & 30 & 1.3\% & 0.67 [0.12, 3.57] \\ & \text{Marak 2010} & 5 & 30 & 4 & 30 & 1.7\% & 0.50 [0.06, 1.29] \\ & \text{Turan 2008} & 0 & 20 & 0 & 20 & \text{Not estimable} \\ & \text{Unlugenc 2005} & 2 & 30 & 4 & 30 & 1.7\% & 0.50 [0.02, 1.64] \\ & \text{Mu 2011} & 1 & 20 & 6 & 22 & 2.6\% & 0.77 [0.02, 1.26] \\ & \text{Mu 2011} & 1 & 20 & 6 & 25 & 0.7\% & 0.38 [0.07, 0.28] \\ & \text{Mu 2011} & 1 & 20 & 6 & 225 & 0.7\% & 0.50 [0.02, 1.64] \\ & \text{Mu 2011} & 1 & 20 & 5.7 & 0.38 [0.07, 0.28] \\ & \text{Mu 2011} & 1 & 20 & 5.7 & 0.38 [0.07, 0.28] \\ & \text{Hetrogeneity: Chi" = 2.399, df = 25 (P = 0.5;); P = 0\% \\ & \text{Test for overall effect: Z = 5.49 (P < 0.00001) \\ & \text{1.22 Regional anesthesia} \\ & \text{Agarwal 2014} & 0 & 25 & 0 & 25 & 0.7\% & 0.50 [0.05, 5.17] \\ & \text{Dinesh 2014} & 2 & 50 & 0 & 50 & 0.2\% & 5.00 [0.25, 101.68] \\ & \text{Hetrogeneity: Chi" = 2.39, df = 25 (P = 0.5;); P = 0\% \\ & \text{Test for overall effect: Z = 5.74 (P < 0.00001) \\ & \text{1.22 Regional anesthesia} \\ & \text{Agarwal 2014} & 0 & 25 & 0 & 25 & 0.7\% & 0.50 [0.05, 5.17] \\ & \text{Dinesh 2014} & 1 & 25 & 2 & 25 & 0.9\% & 0.50 [0.05, 5.17] \\ & \text{Dinesh 2014} & 1 & 40 & 2 & 38 & 0.9\% & 0.50 [0.05, 5.17] \\ & \text{Dinesh 2014} & 1 & 40 & 2 & 38 & 0.9\% & 0.47 [0.09, 0.48] \\ & \text{Agarwal 2014} & 6 & 40 & 4 & 40 & 1.7\% & 1.50 [0.46, 4.91] \\ & \text{Agarwal 2014} & 1 & 40 & 2 & 38 & 0.9\% & 0.47 [0.00, 0.48] \\ & \text{Agarwal 2014} & 1 & 40 & 2 & 38 & 0.9\% & 0.47 [0.05, 5.1141] \\ & \text{Subtotal (95\% CI)} & 126 & 465 & 18.4\% & 0.78 [0.51, 1.1$	Gurbet 2006	6	25	15	25	6.5%	0.40 [0.19, 0.86]	
$ \begin{aligned} & sk 2006 & 1 & 21 & 2 & 21 & 0.9\% & 0.50 0.05, 5.10 \\ Kim a 2013 & 18 & 46 & 26 & 44 & 11.3\% & 0.68 0.41, 4.22 \\ Kim 2 2013 & 1 & 28 & 42 & 43^* & 0.13 0.002, 0.87 \\ Mazanikov 2013 & 2 & 25 & 1 & 25 & 0.4\% & 0.50 0.24, 1.04 \\ Mazanikov 2013 & 2 & 25 & 1 & 25 & 0.4\% & 0.20 0.9, 20.67 \\ Mazanikov 2013 & 2 & 30 & 3 & 30 & 1.3\% & 0.67 0.12, 3.71 \\ Mirznk 2010 & 5 & 30 & 8 & 30 & 3.5\% & 0.63 0.23, 1.89 \\ Mirznk 2013 & 2 & 20 & 3 & 20 & 1.3\% & 0.67 0.12, 3.57 \\ Oxtone 2006 & 2 & 20 & 3 & 20 & 1.3\% & 0.67 0.12, 3.57 \\ Oxtone 2006 & 2 & 20 & 3 & 20 & 1.3\% & 0.67 0.12, 3.57 \\ Urafnoyulina 2006 & 5 & 20 & 13 & 20 & 5.7\% & 0.38 0.01, 7.0.88 \\ Turan 2008 & 0 & 20 & 0 & 20 & Not estimable \\ Unlugenc 2005 & 2 & 30 & 4 & 30 & 1.7\% & 0.50 0.02, 1.68 \\ Vu 2011 & 1 & 20 & 6 & 20 & 2.6\% & 0.17 0.02, 1.26 \\ Tuber 2005 & 6 & 25 & 10 & 25 & 4.4\% & 0.60 0.263 4.01 \\ Vu 2013 & 1 & 40 & 5 & 40 & 2.2\% & 0.20 0.02, 1.64 \\ Vidiz 2006 & 6 & 25 & 10 & 25 & 4.4\% & 0.60 0.26 1.48 \\ Subtotal (95\% Cl) & 782 & 773 & 81.6\% & 0.57 0.46 & 0.69 4.27 \\ Tate events & 106 & 186 \\ Heterogeneity: Ch2 = 23.99, df = 25 (P = 0.52; P = 0.5\% & 1.50 0.27, 8.34 \\ Gupta a 2011 & 0 & 25 & 0 & 25 & Not estimable \\ Amarakb 2014 & 1 & 25 & 0 & 25 & Not estimable \\ Amarakb 12014 & 1 & 25 & 0 & 25 & Not estimable \\ Amarakb 12014 & 1 & 25 & 0 & 25 & 0.50 0.05, 5.72 \\ Hoterogeneity: Ch2 = 23.99, df = 25 (P = 0.52; P = 0.5\% & 1.50 0.27, 8.34 \\ Gupta a 2011 & 1 & 30 & 2 & 30 & 0.9\% & 0.50 0.05, 5.52 \\ Hoterogeneity: Ch2 = 18.82, df = 11 (P = 0.06); P = 42\% \\ Tatle vents & 132 & 42 \\ Heterogeneity: Ch2 = 18.82, df = 11 (P = 0.06); P = 42\% \\ Tatle vents & 132 & 42 \\ Heterogeneity: Ch2 = 18.82, df = 11 (P = 0.21); P = 15\% \\ Total events & 32 & 42 \\ Heterogeneity: Ch2 = 18.82, df = 11 (P = 0.21); P = 128 \\ Heterogeneity: Ch2 = 18.82, df = 11 (P = 0.06); P = 42\% \\ Test for overall effect: Z = 5.17 (P < 0.0001) \\ Hoter Stard 10 = 500; F = 18.82, df = 11 (P = 0.06); P = 42\% \\ Test for overall effect: Z = 5.17 (P$	Gyanesh 2014	2	52	3	46	1.4%	0.59 [0.10, 3.38]	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	lsik 2006	1	21	2	21	0.9%	0.50 [0.05, 5.10]	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Kim a 2013	8	25	5	25	2.2%	1.60 [0.61, 4.22]	
Lee 2013 1 28 8 29 34% 0.13 [0.02, 0.97] Massal 2009 8 42 15 39 68% 0.50 [0.24, 1.04] Massal 2013 2 25 1 25 0.4% 2.00 [0.19, 20.67] Mizrak 2013 2 30 3 30 1.3% 0.67 [0.12, 3.57] Mizrak 2010 5 30 8 30 3.5% 0.63 [0.23, 1.69] Othani 2011 3 16 2 16 0.9% 1.50 [0.29, 7.81] Oxtase 2006 2 2 0.3 20 1.3% 0.67 [0.12, 3.57] Shin 2013 2 21 3 22 1.3% 0.67 [0.12, 3.57] Tufanoguliar 2008 5 2.0 13 20 5.7% 0.38 [0.17, 0.88] Turan 2008 0 20 0 20 Not estimable Unlugenc 2005 2 30 4 30 1.7% 0.50 [0.02, 2.13] Unlugenc 2005 2 30 4 30 1.7% 0.50 [0.10, 2.53] Wu 2011 1 20 6 20 26% 0.71 [0.02, 1.26] Unlugenc 2006 6 25 10 25 44% 0.50 [0.02, 5.14] Jikiz 2006 6 25 10 25 44% 0.50 [0.02, 5.14] Jikiz 2006 6 25 10 25 44% 0.50 [0.02, 5.14] Tutan 2014 0 30 4 30 2.0% 0.51 [0.04, 1.69] Subtoal (95% CI) 752 773 61.6% 0.57 [0.46, 0.69] Tict or overall effect. Z = 5.49 (P < 0.0001) 1.22 Regional anesthesia Amarakbi 2014 1 25 2 25 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.25, 10.158] Elicicak 2010 3 30 2 30 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.19, 2.09] Goku 2008 5 30 25 32 10.5% 0.21 [0.09, 0.48] Goku 2008 5 30 25 32 10.6% 0.21 [0.09, 0.48] Mizrak 2014 1 25 2 26 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.28, 10.158] Elicicak 2010 3 30 2 30 0.9% 0.50 [0.05, 5.2] Hong 2012 2 2 26 1 25 0.4% 0.21 [0.09, 0.48] Mizrak 2010 0 15 0 15 Not estimable Mizrak 2010 0 15 0 15 Not estimable Mizrak 2010 1 3 20 2.00 2.2% 3.00 [0.33, 26.82] Mizrak 2011 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shari 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shari 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shari 2014 1 20 20 0.22% 3.00 [0.55, 51.14] Jin 2012 0 30 0 30 Not estimable Mizrak 2014 5 20 0 22 0.9% 2.50 [0.55, 51.14] Jin 2012 0 13 0 0 20 0.2% 3.00 [0.33, 26.82] Tatheen 2013 1 20 0 20 0.2% 3.00 [0.55, 51.14] Jun 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Tatheen 2013 1 20 0 20 0.2% 3.00 [0.55, 51.14] Jun 2016 Vertis 32 42 Heterogeneeity: Chi = 182, df = 11 (P = 0.02); I ² = 15% Total evertis 132 24 Heter	Kim b 2013	18	46	26	46	11.3%	0.69 [0.45, 1.08]	-
$ \begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	Lee 2013	1	28	8	29	3.4%	0.13 [0.02, 0.97]	
$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	Massad 2009	8	42	15	39	6.8%	0.50 [0.24, 1.04]	
Mizrak 2013 2 30 3 30 1.3% 0.67 [0.12, 3.71] Mizrak 2010 5 30 8 30 1.3% 0.67 [0.12, 3.7] Othani 2011 3 16 2 16 0.9% 1.50 [0.29, 7.81] Ozkose 2006 2 20 3 20 1.3% 0.67 [0.12, 3.57] Shin 2013 2 21 3 21 1.3% 0.67 [0.12, 3.57] Turan 2008 5 20 13 20 5.7% 0.38 [0.17, 0.88] Turan 2008 5 20 13 20 5.7% 0.38 [0.17, 0.88] Unlugenc 2005 2 30 4 30 1.7% 0.50 [0.10, 2.53] Wu 2011 1 20 6 20 2.6% 0.17 [0.02, 1.26] Wu 2011 1 20 6 20 2.6% 0.17 [0.02, 1.26] Total events 1 06 186 Agarwal 2014 0 30 4 30 2.0% 0.11 [0.01, 1.98] Total events 1 06 186 Agarwal 2014 0 25 0 25 Not estimable Almarakb 2014 0 25 0 25 Not estimable Almarakb 2014 0 25 0 25 Not estimable Almarakb 2014 1 25 2 25 0.9% 0.50 [0.26, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.26, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.26, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.26, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.26, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.06, 5.21] Hong 2012 2 2 66 1 25 0.4% 0.00 [0.38, 26.92] Hong 2012 2 2 66 1 25 0.4% 0.00 [0.33, 26.92] Ne of the 23.99 .04 (0.0001) Mizrak 2011 1 30 2 30 0.9% 0.50 [0.06, 5.22] Hong 2012 2 2 66 1 25 0.4% 0.90 [0.38, 6.22] Ne of the 2013 1 20 0 20 0.2% 0.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Mizrak 2014 1 20 0 20 0.2% 0.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Mizrak 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Not estimable Mizrak 2014 1 20 0 20 0.2% 0.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Tekin 2007 0 30 0 30 Not estimable Mizrak 2014 1 40 2 28 0.9% 0.47 [0.05, 1.14] Subtotal [95% CI) 128 [128 100.9% 0.61 [0.50, 0.73] Tekin 2007 0 30 0 30 Not estimable Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21); P = 15% Total events 1 38 (228 Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21); P = 15% Total events 1 38 (228 Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21); P = 15% Total events 1 38 (228 Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21); P = 15% Total events 1 38 (228 Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21);	Mazanikov 2013	2	25	1	25	0.4%	2.00 [0.19, 20.67]	
Mizrak a 2010 5 30 8 30 3.5% 0.63 [0.23, 1.69] Czkose 2006 2 20 3 20 1.3% 0.67 [0.12, 3.57] Shin 2013 2 21 3 21 1.3% 0.67 [0.12, 3.59] Singh 2012 2 40 7 40 3.0% 0.29 [0.06, 1.29] Tufanogulari 2008 5 20 13 20 5.7% 0.38 [0.17, 0.88] Unlugenc 2005 2 30 4 30 1.7% 0.50 [0.10, 2.53] Wu 2011 1 20 6 20 2.6% 0.17 [0.02, 1.64] Wu 2013 1 40 5 40 2.2% 0.20 [0.26, 1.40] Vu 2013 1 40 5 40 2.2% 0.20 [0.26, 1.40] Yidiz 2006 6 25 10 25 4.4% 0.60 [0.26, 1.40] Subtotal (95% Ch) 782 773 81.6% 0.57 [0.46, 0.68] Call events 106 186 Heterogeneity: Chi ² = 25.49 (P < 0.0001) 1.2.2 Regional anesthesia Agarwal 2014 0 25 0 25 Not estimable Amarakbi 2014 1 25 2 25 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.26, 1.40] Jain 2012 2 2 61 25 0.4% 3.00 [0.26, 1.40] Jain 2014 0 30 2 30 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.5% 0.2% 5.00 [0.26, 1.78] Elcicek 2010 3 30 2 30 0.9% 0.50 [0.05, 5.17] Dinesh 2014 1 30 2 30 0.9% 0.50 [0.05, 5.17] Dinesh 2014 1 30 2 30 0.9% 0.50 [0.05, 5.22] Hong 2012 2 2 61 1 25 0.4% 3.00 [0.23, 0.16, 8] Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 1 3 20 2.00 0.30 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 1 3 25 1 25 0.4% 3.00 [0.33, 26.92] Nie 2014 1 0 0 20 0.2% 3.00 [0.55, 5.27] Tathene 2013 1 2 20 0.9% 0.50 [0.05, 5.22] Test for overall effect: Z = 1.14 (P = 0.26); P = 42% Test for overall effect: Z = 1.14 (P = 0.27); P = 15% Total events 1 38 228 Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21); P = 15% Total events 1 38 228 Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21); P = 15% Total events 1 38 228 Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21); P = 15% Total events 1 38 228 Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21); P = 15% Total events 1 38 (228 Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21); P = 15% Total events 1 38 (228 Heterogeneity: Chi ² = 4.367, df = 37 (P = 0.21); P = 15%	Mizrak 2013	2	30	3	30	1.3%	0.67 [0.12, 3.71]	
Ottani 2011 3 16 2 16 0.9% 1.50 [0.2, 7.81] Octases 2006 2 20 3 20 1.3% 0.67 [0.12, 3.57] Sing 2012 2 2 40 7 40 3.0% 0.29 [0.06, 1.29] Singh 2012 2 40 7 40 3.0% 0.29 [0.06, 1.29] Turan 2008 5 20 13 20 5.7% 0.38 [0.17, 0.86] Turan 2008 0 20 0 20 Not estimable Unlugenc 2005 2 30 4 30 1.7% 0.50 [0.10, 2.53] Wu 2011 1 20 6 20 2.6% 0.17 [0.02, 1.26] Wu 2013 1 40 5 40 2.2% 0.20 [0.02, 1.64] Yular 2006 6 25 10 2.5 4.4% 0.60 [0.26, 1.40] Zhao 2014 0 30 4 30 2.0% 0.11 [0.01, 1.98] Subtotal (9% CI) 762 2.399, df = 25 (P = 0.52); P = 0% Test for overall effect: Z = 5.49 (P < 0.00001) 1.2.2 Regional anesthesia Agarwal 2014 0 25 0 25 Not estimable Heterogeneity: Chi ^P = 23.99, df = 25 0 25 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.25, 107.58] Elicicek 210 3 30 2 30 0.9% 1.50 [0.27, 8.34] Esmacglu 2013 2 30 1 30 0.4% 0.20 [0.09, 0.48] Gupta 2011 1 30 2 30 0.9% 0.50 [0.05, 6.17] Jain 2012 2 26 1 25 0.4% 1.92 [0.19, 19.90] Jain 2012 2 26 1 25 0.4% 0.09 0.01 [0.50, 0.78] Mizrak 52010 0 15 0 15 Not estimable Necgi 2010 3 25 1 25 0.4% 0.01 [0.4, 4.91] Tache 2014 1 40 2 38 0.9% 0.47 [0.04, 6.03] Shahi 2014 1 40 2 38 0.9% 0.47 [0.04, 6.03] Shahi 2014 1 40 2 38 0.9% 0.47 [0.04, 6.03] Shahi 2014 1 40 2 38 0.9% 0.47 [0.04, 6.03] Shahi 2014 1 40 2 38 0.9% 0.47 [0.04, 6.03] Shahi 2014 1 40 2 38 0.9% 0.47 [0.04, 6.03] Shahi 2014 1 40 2 38 0.9% 0.47 [0.04, 6.03] Shahi 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (9% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total (9% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 3 2 42 Heterogeneity: Chi ^P = 4.367, df = 37 (P = 0.21); P = 15% Total (9% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 -228 Heterogeneity: Chi ^P = 4.367, df = 37 (P = 0.21); P = 15% Total events 138 -228 Heterogeneity: Chi ^P = 4.367, df = 37 (P = 0.21); P = 15% Total events 138 -228 Heterogeneity: Chi ^P = 4.367, df = 37 (P = 0.21); P = 15%	Mizrak a 2010	5	30	8	30	3.5%	0.63 [0.23, 1.69]	
$\begin{array}{c} 0 \mbox{zckses} 2006 & 2 & 20 & 3 & 20 & 1.3\% & 0.67 [0.12, 3.57] \\ Singh 2012 & 2 & 40 & 7 & 40 & 3.0\% & 0.29 [0.06, 1.29] \\ Tufanogullari 2008 & 5 & 20 & 13 & 20 & 5.7\% & 0.38 [0.17, 0.88] \\ Turan 2008 & 0 & 20 & 0 & 20 & Not estimable \\ Unlugenc 2005 & 2 & 30 & 4 & 30 & 1.7\% & 0.50 [0.10, 2.53] \\ Wu 2011 & 1 & 20 & 6 & 20 & 2.6\% & 0.17 [10.02, 1.26] \\ Wu 2013 & 1 & 40 & 5 & 40 & 2.2\% & 0.20 [0.02, 1.64] \\ Yildiz 2006 & 6 & 25 & 10 & 25 & 4.4\% & 0.66 [0.26, 1.40] \\ Zhao 2014 & 0 & 30 & 4 & 30 & 2.0\% & 0.11 [0.01, 1.98] \\ Subtotal (95\% CI) & 782 & 773 & 81.6\% & 0.57 [0.46, 0.69] \\ Test for overall effect: Z = 5.49 (P < 0.00001) \\ 1.2.2 Regional anesthesia \\ Agarwal 2014 & 0 & 25 & 0 & 25 & Not estimable \\ Almaraki 2014 & 1 & 25 & 2 & 25 & 0.9\% & 0.50 [0.25, 1.158] \\ Elcicek 2010 & 3 & 30 & 2 & 30 & 0.9\% & 1.50 [0.27, 8.34] \\ Semaoglu 2013 & 2 & 30 & 1 & 30 & 0.4\% & 2.00 [0.15, 5.71] \\ Dinesh 2014 & 1 & 30 & 2 & 30 & 0.9\% & 0.50 [0.05, 5.71] \\ Goku 2008 & 5 & 30 & 25 & 32 & 10.5\% & 0.21 [0.09, 0.48] \\ Gupta a 2011 & 1 & 30 & 2 & 30 & 0.9\% & 0.50 [0.05, 5.22] \\ Hong 2012 & 2 & 26 & 1 & 25 & 0.4\% & 3.00 [0.33, 26.92] \\ Nie 2014 & 1 & 40 & 2 & 38 & 0.9\% & 0.47 [[0.04, 5.03] \\ Nie zko 2010 & 3 & 25 & 1 & 25 & 0.4\% & 3.00 [0.33, 26.92] \\ Nie 2014 & 1 & 40 & 2 & 38 & 0.9\% & 0.47 [[0.04, 5.03] \\ Nie zko 2014 & 5 & 20 & 2 & 20 & 0.9\% & 0.78 [[0.55, 11.41] \\ Subtotal (95\% CI) & 1248 & 1238 & 100.0\% & 0.61 [[0.50, 0.73] \\ Total events & 32 & (\mu = 2.2\%) \\ Test for overall effect: Z = 1.14 (P = 0.05); P = 0.21; P = 15\% \\ Total events & 138 & 228 \\ Heleroggeneity: Chip = 43.67, df = 37 (P = 0.001) \\ = Eavors [dargendetimical E = Eavors; [dargend$	Ohtani 2011	3	16	2	16	0.9%	1.50 [0.29, 7.81]	
Shin 2013 2 2 21 3 21 1.3% 0.67 [0.12, 3.59] Singh 2012 2 2 40 7 40 3.0% 0.29 [0.6, 1.29] Turan 2008 5 20 13 20 5.7% 0.38 [0.17, 0.88] Turan 2008 0 20 0 20 Not estimable Unlugenc 2005 2 30 4 30 1.7% 0.50 [0.10, 2.53] Wu 2011 1 20 6 20 2.6% 0.17 [0.02, 1.26] Wu 2013 1 40 5 40 2.2% 0.20 [0.02, 1.64] Total events 106 186 Heterogeneity: Chi ^P = 13.9; 0 + 25 (P = 0.52); P = 0% Test for overall effect: Z = 5.49 (P < 0.00001) Laze 2 5 0.9% 0.50 [0.10, 2.7, 3.4] Elicicek 2010 3 30 2 50 0.2% 5.00 [0.25, 101.88] Elicicek 2010 3 30 2 50 0.9% 1.50 [0.27, 8.34] Esmaogiu 2013 2 30 0.9% 1.50 [0.27, 8.34] Esmaogiu 2013 2 30 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.27, 8.34] Esmaogiu 2013 2 30 1 30 0.4% 2.00 [0.9, 0.48] Cupta a 2011 1 30 2 30 0.9% 0.50 [0.05, 5.22] Hong 2012 2 26 1 25 0.4% 0.50 [0.05, 0.28] Hong 2012 2 26 1 25 0.4% 0.50 [0.05, 0.00] Mizrak 2010 0 15 0 15 Not estimable Nee gi2010 3 25 1 25 0.4% 0.20 [0.9, 0.48] Mizrak 2010 0 15 0 15 Not estimable Nee gi2010 3 25 1 25 0.4% 0.50 [0.05, 5.17] Tatelevents 12 0 0.30 0 30 Not estimable Nee gi2010 3 25 1 25 0.4% 0.50 [0.05, 5.22] Hong 2012 2 2 6 1 25 0.4% 0.50 [0.05, 5.17] Tatelevents 32 42 Heterogeneity: Chi ^P = 18.82, di = 11 (P = 0.06); P = 42% Test for overall effect: Z = 1.14 (P = 0.05); P = 15% Total (95% Cl) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi ^P = 43.67, di = 37 (P = 0.21); P = 15% Total (95% Cl) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi ^P = 43.67, di = 37 (P = 0.21); P = 15% Total (95% Cl) 1248 1238 100.0% 0.61 [0.50, 0.73] Test for overall effect: Z = 1.14 (P = 0.25); P = 0.21; P = 15% Total events 138 228 Heterogeneity: Chi ^P = 43.67, di = 37 (P = 0.21); P = 15% Total events 138 228 Heterogeneity: Chi ^P = 43.67, di = 37 (P = 0.21); P = 15% Total events 10 accention 100 Test for overall effect: Z = 1.70; P = 0.0001	Ozkose 2006	2	20	3	20	1.3%	0.67 [0.12, 3.57]	
Singh 2012 2 40 7 40 3.0% 0.29 [0.06, 1.29] Turanogullari 2008 5 20 13 20 5.7% 0.38 [0.17, 0.88] Turan 2008 0 20 0 20 Not estimable Unlugenc 2005 2 30 4 30 1.7% 0.50 [0.10, 2.53] Wu 2011 1 20 6 20 2.6% 0.17 [10.02, 1.64] Yildiz 2006 6 25 10 25 4.4% 0.66 [0.26, 1.44] Zhao 2014 0 30 4 30 2.0% 0.11 [0.01, 1.98] Subtotal (95% CI) 762 777 81.6% 0.57 [0.46, 0.69] Total events 106 186 Heterogeneity: Chi ² = 23.99, df = 25 (P = 0.52); P = 0% Test for overall effect: Z = 5.49 (P < 0.00001) 1.2.2 Regional anesthesia Agarwal 2014 0 25 0 25 Not estimable Almarakbi 2014 1 25 2 25 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 500 0 50 0.2% 5.00 [0.25, 10.18] Eclicek 2010 3 30 2 30 0.9% 1.50 [0.27, 8.34] Esmaoglu 2013 2 30 1 30 0.4% 2.00 [0.19, 20.90] Goksu 2008 5 3 30 25 32 10.5% 0.21 [10.90, 0.48] Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 0 15 Not estimable Mizrak b 2010 0 15 0 0 15 Not estimable Mizrak b 2010 0 3 0 0 30 Not estimable Mizrak b 2010 1 1 20 0 20 0.2% 3.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 6.03] Tarkeeh 2013 1 20 0 20 0.2% 3.00 [0.33, 26.92] Test for overall effect: Z = 1.14 (P = 0.06); P = 42% Test for overall effect: Z = 1.14 (P = 0.25) Total events 138 228 Heterogeneity: Chi ² = 4.36.7, df = 37 (P = 0.021); P = 15% Total (95% CI) 1 248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi ² = 4.36.7, df = 37 (P = 0.021); P = 15% Total (95% CI) 1 248 1238 100.0% Dist [0 coverall effect: Z = 1.14 (P = 0.25) Total (95% CI) 1 248 1238 100.0% Dist [0 coverall effect: Z = 1.14 (P = 0.25) Total (95% CI) 1 248 1238 100.0% Dist [0 coverall effect: Z = 1.14 (P = 0.25) Total events 138 28 Heterogeneity: Chi ² = 4.36.7, df = 37 (P = 0.0001) Exercise [dargedictomicing]. Exercise [dargedictomicing]. Exercise [dargedictomicing]. Exercise [dargedictomicing]. Exercise [dargedictomicing]. Exercise [dargedictomicing]. Exercis [dargedictomicing]. Exercise [dargedicto	Shin 2013	2	21	3	21	1.3%	0.67 [0.12, 3.59]	
Turan 2008 5 20 13 20 5.7% 0.38 [0.17, 0.88] Unlugen 2005 2 30 4 30 1.7% 0.50 [0.10, 2.53] Wu 2011 1 20 6 20 2.6% 0.17 [0.02, 1.26] Wu 2013 1 40 5 40 2.2% 0.20 [0.02, 1.64] Yildiz 2006 6 25 10 25 4.4% 0.60 [0.26, 1.40] Taba 2014 0 30 4 30 2.0% 0.57 [0.46, 0.69] Total events 106 186 Heterogeneity: Ch ² = 23.99, df = 25 (P = 0.52); P = 0% Test for overall effect Z = 5.49 (P < 0.00001) 1.2.2 Regional anesthesia Agarwal 2014 0 25 0 25 Not estimable Almarakbi 2014 1 25 2 25 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.19, 20.90] Goksu 2008 5 30 25 32 10.5% 0.21 [0.09, 0.48] Esmaoglu 2013 2 30 1 30 0.4% 2.00 [0.19, 20.90] Goksu 2008 5 30 25 32 10.5% 0.21 [0.09, 0.48] Licker 2010 1 3 30 2 30 0.3% Not estimable Neogi 2010 3 25 1 25 0.4% 3.00 [0.33, 26.92] Hong 2012 2 26 1 25 0.4% 3.00 [0.33, 26.92] Hong 2012 3 2 20 0 20 0.2% 3.00 [0.36, 5.22] Hong 2012 3 2 20 0 20 0.2% 3.00 [0.36, 5.22] Hong 2014 1 40 2 38 0.9% 0.47 [10.46, 5.03] Jain 2012 0 30 0 30 Not estimable Neogi 2010 3 25 1 25 0.4% 3.00 [0.33, 26.92] Tarbeh 2013 1 20 0 20 0.2% 3.00 [0.46, 4.91] Tarbeh 2013 1 20 0 20 0.2% 0.00 [0.36, 50.22] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Tarbeh 2013 1 20 0 20 0.2% 3.00 [0.13, 69.52] Total events 32 42 Heterogeneity: Ch ² = 1.8.82, df = 11 (P = 0.06); P = 42% Test for overall effect Z = 1.34, Cf = 37 (P = 0.21); P = 15% Total events 138 22 Heterogeneity: Ch ² = 43.67, df = 37 (P = 0.21); P = 15% Total events 138 20 (P = 0.21); P = 15% Total events 138 7 (P = 0.21); P = 15% Total events 138 7 (P = 0.21); P = 15% Total events 138 7 (P = 0.21); P = 15% Total events 138 7 (P = 0.21); P = 15% Total events 138 7 (P = 0.21); P = 15% Total events 138 7 (P = 0.21); P = 15% Test for overall effect Z = 3.73 (P = 0.21); P = 15%	Singh 2012	2	40	7	40	3.0%	0.29 [0.06, 1.29]	
Turan 2008 0 20 10 20 Not estimable Unlugenc 2005 2 30 4 30 1.7% 0.50 [0.10, 2.53] Wu 2011 1 20 6 20 2.6% 0.17 [0.02, 1.26] Wu 2013 1 40 5 40 2.2% 0.20 [0.02, 1.64] Wu 2013 1 40 5 40 2.2% 0.20 [0.02, 1.64] Wu 2013 1 40 5 40 2.2% 0.20 [0.02, 1.64] The 2014 0 30 4 30 2.2% 0.11 [0.01, 1.98] Total events 106 186 Heterogeneity: Ch ² = 23.99, df = 25 (P = 0.52); P = 0% Test for overall effect: Z = 5.49 (P < 0.0001) 1.2.2 Regional anesthesia Agarwal 2014 0 25 0 25 Not estimable Almarakbi 2014 1 25 2 25 0.9% 0.50 [0.25, 10.58] Heterogeneity: Ch ² = 23.99, df = 25 (P < 0.52); P = 0% Test for overall effect: Z = 5.49 (P < 0.0001) 1.2.2 Regional anesthesia Agarwal 2014 0 25 0 25 Not estimable Almarakbi 2014 1 25 2 25 0.09% 0.50 [0.25, 10.58] Hong 2012 2 20 0 50 0.2% 5.00 [0.25, 10.58] Hong 2012 2 2 26 1 25 0.4% 1.92 [0.19, 19.90] Jain 2012 0 30 0 30 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Neegi 2010 3 25 1 25 0.4% 0.078 [0.05, 5.22] Textin 2007 0 30 0 30 Not estimable Wize 14 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shahi 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% Cl) 466 465 18.4% 0.78 [0.51, 1.19] Total events 32 42 Heterogeneity: Ch ² = 43.67, df = 37 (P = 0.21); P = 15% Test for overall effect: Z = 5.37 (P < 0.201); P = 15% Test for overall effect: Z = 5.37 (P < 0.201); P = 15% Test for overall effect: Z = 5.37 (P < 0.201); P = 15% Test for overall effect: Z = 5.37 (P < 0.201); P = 15% Test for overall effect: Z = 5.37 (P < 0.201); P = 15%	Tufanogullari 2008	5	20	13	20	5.7%	0.38 [0.17, 0.88]	
Unlagen 2005 2 30 4 30 1.7% 0.50 [0.10, 2.53] Wu 2011 1 2 0 6 20 2.6% 0.17 [0.02, 1.26] Wu 2013 1 40 5 40 2.2% 0.20 [0.02, 1.64] Yildz 2006 6 25 10 25 4.4% 0.60 [0.26, 1.40] Zhao 2014 0 30 4 30 2.0% 0.11 [0.01, 1.98] Subtotal (95% CI) 782 773 81.6% 0.57 [0.46, 0.69] Total events 106 186 Heterogeneity: Ch ² = 23.99, df = 25 (P = 0.52); P = 0% Test for overall effect: Z = 5.49 (P < 0.00001) 1.2.2 Regional anesthesia Agarwal 2014 0 25 0 25 Not estimable Almarakbi 2014 1 25 2 25 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.25, 101.58] Elicicek 2010 3 30 2 30 0.9% 1.50 [0.27, 8.34] Elicicek 2010 3 30 25 32 10.5% 0.21 [0.99, 0.48] Gupta a 2011 1 30 2 30 0.9% 0.50 [0.05, 5.52] Heat 2011 1 30 2 30 0.9% 0.50 [0.05, 5.22] Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2013 2 2 20 0.2% 3.00 [0.3, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Heat 3.32 42 Heterogeneity: Ch ² = 43.67, df = 37 (P = 0.02)); P = 15% Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Ch ² = 43.67, df = 37 (P = 0.020); P = 42% Test for overall effect: Z = 5.37 (P = 0.0001)	Turan 2008	0	20	0	20		Not estimable	
Wu 2011 1 20 6 20 2.6% 0.17 [0.02, 1.26] Yildiz 2006 6 25 10 25 4.4% 0.60 [0.26, 1.40] Zhao 2014 0 30 4 30 2.0% 0.11 [0.01, 1.98] Zhao 2014 0 30 4 30 2.0% 0.57 [0.46, 0.69] Total events 106 186 Heterogeneity: Chi ² = 23.99, df = 25 (P = 0.52); P = 0% Test for overall effect; Z = 5.48 (P < 0.00001)	Unlugenc 2005	2	30	4	30	1.7%	0.50 [0.10, 2.53]	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Wu 2011	1	20	6	20	2.6%	0.17 [0.02, 1.26]	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Wu 2013	1	40	5	40	2.2%	0.20 [0.02, 1.64]	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Yildiz 2006	6	25	10	25	4.4%	0.60 [0.26, 1.40]	
Substitution (5% Cl) 762 77, 5 0.15% 0.57 [0.46, 0.69] Total events 106 186 Heterogeneity: $Chi^2 = 23.99$, df = 25 (P = 0.52); P = 0% Test for overall effect: Z = 5.49 (P < 0.00001) 1.2.2 Regional anesthesia Agarval 2014 0 25 0 25 Not estimable Almarakbi 2014 1 25 2 25 0.5% 0.50 [0.25, 101.58] Elcicek 2010 3 30 2 30 0.9% 1.50 [0.27, 8.44] Esmaoglu 2013 2 30 1 30 0.4% 2.00 [0.19, 20.90] Goksu 2008 5 30 25 32 10.5% 0.21 [0.09, 0.48] Gupta a 2011 1 30 2 30 0.9% 0.50 [0.05, 5.22] Hong 2012 2 2 6 1 25 0.4% 1.92 [0.19, 19.90] Jain 2012 0 30 0 30 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Neegi 2010 3 25 1 25 0.4% 3.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shahi 2014 6 40 4 40 1.7% 1.50 [0.46, 4.91] Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.13, 68.52] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% Cl) 466 445 18.4% 0.78 [0.51, 1.19] Total events 32 42 Heterogeneity: Chi ² = 18.82, df = 11 (P = 0.06); P = 42% Test for overall effect: Z = 1.14 (P = 0.21); P = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); P = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); P = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); P = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); P = 15% Total events 138 228 Heterogeneity: Chi ² = 5.37 (P < 0.00001) Eavoure Idexmediatomiding Eavoure Idexmediatomiding Ea	Zhao 2014 Subtatal (05% CI)	0	30	4	30	2.0%	0.11 [0.01, 1.98]	▲
Total events 106 PC 100 PC 10	Subtotal (95% CI)	100	102	100	115	01.0%	0.57 [0.46, 0.69]	•
Test for overall effect: $Z = 5.49$ (P < 0.0001) 1.2.2 Regional anesthesia Agarwal 2014 0 25 0 25 Not estimable Almarakbi 2014 1 25 2 25 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.25, 101.86] Elcicek 2010 3 30 2 30 0.9% 1.50 [0.27, 8.34] Esmaoglu 2013 2 30 1 30 0.4% 2.00 [0.19, 20.90] Goksu 2008 5 30 25 32 10.5% 0.21 [0.09, 0.48] Gupta a 2011 1 30 2 30 0.9% 0.50 [0.05, 5.22] Hong 2012 2 26 1 25 0.4% 1.32 [0.19, 19.90] Jain 2012 0 30 0 30 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Mizrak b 2010 0 15 0 20 0.2% 3.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shahi 2014 6 40 4 40 1.7% 1.50 [0.46, 4.91] Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.13, 69.52] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Total events 138 224 Heterogeneity: Chi ² = 18.82, df = 11 (P = 0.06); I ² = 42% Test for overall effect: Z = 5.37 (P = 0.21); I ² = 15% Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15%	I otal events	106 200 df = 25 (D - 0 52	180				
1.2.2 Regional anesthesia Agarwal 2014 0 25 0 25 Not estimable Almarakbi 2014 1 25 2 25 Not estimable Almarakbi 2014 1 25 2 25 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.27, 8.34] Ecnaeglu 2013 2 30 1 30 0.4% 2.00 [0.19, 20.90] Goksu 2008 5 30 25 32 10.5% 0.21 [0.09, 0.48] Horg 2012 2 26 1 25 0.4% 1.92 [0.19, 19.90] Jain 2012 0 30 0 30 0.9% 0.50 [0.03, 26.92] Niezak b 2010 0 15 Not estimable 1.7% 1.50 [0.46, 4.91] Neegi 2010 3 25 1 25 0.4% 3.00 [0.46, 4.91] Tarbeeh 2013 1 20 20 0.9% 2.50 [0.55, 11.41] 1.45 Subtotal (95% Cl) 465 18.4% 0.78 [0.51, 1.19] 0.01 0.01 <td>Heterogeneity: Chi⁺ = 2</td> <td>23.99, 01 = 25</td> <td>P = 0.52</td> <td>; 1- = 0%</td> <td></td> <td></td> <td></td> <td></td>	Heterogeneity: Chi ⁺ = 2	23.99, 01 = 25	P = 0.52	; 1- = 0%				
1.2.2 Regional anesthesia Agarwal 2014 0 25 0 25 Not estimable Almarakbi 2014 1 25 2 25 0.9% 0.50 [0.26, 5, 17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.27, 6, 34] Esmaoglu 2013 2 30 1 30 0.4% 2.00 [0.19, 20.90] Gokta 2008 5 30 25 32 10.5% 0.21 [0.09, 0.48] Gupta a 2011 1 30 2 30 0.9% 0.50 [0.05, 5.22] Hong 2012 2 26 1 25 0.4% 1.92 [0.19, 19.90] Jain 2012 0 30 0 30 Not estimable Nie 2014 1 40 2 8 0.9% 0.47 [0.04, 5.03] Shahi 2014 6 40 4 0.7% 1.50 [0.46, 4.91] 1 Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.33, 26.92]	rest for overall effect.	2 = 5.49 (P < 0	.00001)					
Agarwal 2014 0 25 0 25 Not estimable Almarakbi 2014 1 25 2 25 0.9% 0.50 [0.05, 5.17] Dinesh 2014 2 50 0 50 0.2% 5.00 [0.25, 101.58] Elcicek 2010 3 30 2 30 0.9% 1.50 [0.27, 8.34] Esmaoglu 2013 2 30 1 30 0.4% 2.00 [0.19, 20.90] Goksu 2008 5 30 2.5 32 10.5% 0.21 [0.09, 0.48] Gupta a 2011 1 30 2 30 0.9% 0.50 [0.05, 5.22] Hong 2012 2 26 1 25 0.4% 1.92 [0.19, 19.90] Jain 2012 0 30 0 30 Not estimable Neig 2010 0 15 Not estimable	1.2.2 Regional anesth	esia						
Almarakbi 2014 1 25 2 25 0.9% 0.50 $[0.05, 5.17]$ Dinesh 2014 2 50 0 50 0.2% 5.00 $[0.25, 101.58]$ Elcicek 2010 3 30 2 30 0.9% 1.50 $[0.27, 8.34]$ Esmaoglu 2013 2 30 1 30 0.4% 2.00 $[0.19, 20.90]$ Goksu 2008 5 30 25 32 10.5% 0.21 $[0.09, 0.48]$ Gupta a 2011 1 30 2 30 0.9% 0.50 $[0.05, 5.22]$ Hong 2012 2 26 1 25 0.4% 1.92 $[0.19, 19.90]$ Jain 2012 0 30 0 30 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Medgi 2010 3 25 1 25 0.4% 3.00 $[0.33, 26.92]$ Nie 2014 1 40 2 38 0.9% 0.47 $[0.04, 5.03]$ Shahi 2014 6 40 4 40 1.7% 1.50 $[0.46, 4.91]$ Tarbeeh 2013 1 20 0 20 0.2% 3.00 $[0.13, 69.52]$ Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 $[0.55, 11.41]$ Subtotal (95% Cl) 466 465 18.4% 0.78 $[0.51, 1.19]$ Total events 32 42 Heterogeneity: Chi ² = 18.82, df = 11 (P = 0.06); I ² = 42% Test for overall effect: Z = 5.37 (P < 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15%	Agarwal 2014	0	25	0	25		Not estimable	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Almarakbi 2014	1	25	2	25	0.9%	0.50 [0.05, 5,17]	
Elcick 2010 3 3 30 2 30 0.9% 1.50 [0.27, 8.34] Esmaoglu 2013 2 30 1 30 0.4% 2.00 [0.19, 20.90] Goksu 2008 5 30 25 32 10.5% 0.21 [0.09, 0.48] Gupta a 2011 1 30 2 30 0.9% 0.50 [0.05, 5.22] Hong 2012 2 26 1 25 0.4% 1.92 [0.19, 19.90] Jain 2012 0 30 0 30 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Neogi 2010 3 25 1 25 0.4% 3.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shahi 2014 6 40 4 40 1.7% 1.50 [0.46, 4.91] Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.13, 69.52] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Total events 32 42 Heterogeneity: Chi ² = 18.82, df = 11 (P = 0.06); I ² = 42% Test for overall effect: Z = 1.14 (P = 0.21); I ² = 15% Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 5.37 (P < 0.00001)	Dinesh 2014	2	50	0	50	0.2%	5.00 [0.25, 101.58]	
Esmaoglu 2013 2 30 1 30 0.4% 2.00 [0.19, 20.90] Goksu 2008 5 30 25 32 10.5% 0.21 [0.09, 0.48] Gupta a 2011 1 30 2 30 0.9% 0.50 [0.05, 5.22] Hong 2012 2 2 26 1 25 0.4% 1.92 [0.19, 19.90] Jain 2012 0 30 0 30 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Neogi 2010 3 25 1 25 0.4% 3.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shahi 2014 6 40 4 40 1.7% 1.50 [0.46, 4.91] Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.13, 69.52] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% Cl) 466 465 18.4% 0.78 [0.51, 1.19] Total events 32 42 Heterogeneity: Chi ² = 18.82, df = 11 (P = 0.06); I ² = 42% Test for overall effect: Z = 1.14 (P = 0.21); I ² = 15% Total (95% Cl) 1 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15% Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); I ² = 15%	Elcicek 2010	3	30	2	30	0.9%	1.50 [0.27, 8.34]	
Goksu 2008 5 30 25 32 10.5% 0.21 [0.09, 0.48] Gupta a 2011 1 30 2 30 0.9% 0.50 [0.05, 5.22] Hong 2012 2 26 1 25 0.4% 1.92 [0.19, 19.90] Jain 2012 0 30 0 30 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Neogi 2010 3 25 1 25 0.4% 3.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shahi 2014 6 40 4 0.7% 1.50 [0.46, 4.91] Tarbeeh 2013 1 20 0.2% 3.00 [0.13, 69.52] Tekin 2007 0 30 0.30 Not estimable Yektas 2014 5 20 2 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Total events 138 228 0.01 0.1 10 0.01	Esmaoglu 2013	2	30	1	30	0.4%	2.00 [0.19, 20.90]	
Gupta a 2011 1 30 2 30 0.9% $0.50[0.05, 5.22]$ Hong 2012 2 26 1 25 0.4% $1.92[0.19, 19.90]$ Jain 2012 0 30 0 30 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Neegi 2010 3 25 1 25 0.4% $3.00[0.33, 26.92]$ Nie 2014 1 40 2 38 0.9% $0.47[0.04, 5.03]$ Shahi 2014 6 40 4 0.2% $3.00[0.13, 69.52]$ Tekin 2007 0 30 0 300 Not estimable Yektas 2014 5 20 2 0.9% $2.50[0.55, 11.41]$ Subtotal (95% CI) 466 465 18.4% $0.78[0.51, 1.19]$ Total (95% CI) 1248 1238 100.0% $0.61[0.50, 0.73]$ Test for overall effect: Z = 1.14 (P = 0.25): 1248 1238 100.0% $0.61[0.50, 0.73]$ Test for overall effect: Z = 5.37 (P < 0.00001) 10 10 1	Goksu 2008	5	30	25	32	10.5%	0.21 [0.09, 0.48]	
Hong 2012 2 26 1 25 0.4% 1.92 [0.19, 19.90] Jain 2012 0 30 0 30 Not estimable Mizrak b 2010 0 15 Not estimable Neogi 2010 3 25 1 25 0.4% 3.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shahi 2014 6 40 4 40 1.7% 1.50 [0.46, 4.91] Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.13, 69.52] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] 466 Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] 466 Heterogeneity: Chi² = 43.67, df = 37 (P = 0.21); l² = 15% 0.01 0.1 1 10 100 Test for overall effect: Z = 5.37 (P < 0.00001) Eavours [dexmedetomidine] <td>Gupta a 2011</td> <td>1</td> <td>30</td> <td>2</td> <td>30</td> <td>0.9%</td> <td>0.50 [0.05, 5.22]</td> <td></td>	Gupta a 2011	1	30	2	30	0.9%	0.50 [0.05, 5.22]	
Jain 2012 0 30 0 30 Not estimable Mizrak b 2010 0 15 0 15 Not estimable Neogi 2010 3 25 1 25 0.4% 3.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shahi 2014 6 40 4 40 1.7% 1.50 [0.46, 4.91] Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.13, 69.52] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Total events 32 42 Heterogeneity: Chi ² = 18.82, df = 11 (P = 0.06); l ² = 42% Test for overall effect: Z = 1.14 (P = 0.25) Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); l ² = 15% 0.01 0.1 10 100 Test for overall effect: Z = 5.37 (P < 0.00001)	Hong 2012	2	26	1	25	0.4%	1.92 [0.19, 19.90]	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Jain 2012	0	30	0	30		Not estimable	
Neogi 2010 3 25 1 25 0.4% 3.00 [0.33, 26.92] Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shahi 2014 6 40 4 40 1.7% 1.50 [0.46, 4.91] Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.13, 69.52] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Image: the standard	Mizrak b 2010	0	15	0	15		Not estimable	
Nie 2014 1 40 2 38 0.9% 0.47 [0.04, 5.03] Shahi 2014 6 40 4 40 1.7% 1.50 [0.46, 4.91] Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.13, 69.52] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Total events 32 42 Heterogeneity: Chi ² = 18.82, df = 11 (P = 0.06); l ² = 42% Test for overall effect: Z = 1.14 (P = 0.25) Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Test for overall effect: Z = 5.37 (P < 0.00001) Eavours [dexmedetomidine] Eavours [dexmedetomidine] Eavours [dexmedetomidine]	Neogi 2010	3	25	1	25	0.4%	3.00 [0.33, 26.92]	
Shahi 2014 6 40 4 40 1.7% 1.50 [0.46, 4.91] Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.13, 69.52] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Total events 32 42 Heterogeneity: Chi² = 18.82, df = 11 (P = 0.06); l² = 42% Test for overall effect: Z = 1.14 (P = 0.25) Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi² = 43.67, df = 37 (P = 0.21); l² = 15% 0.01 0.1 10 100 Test for overall effect: Z = 5.37 (P < 0.00001)	Nie 2014	1	40	2	38	0.9%	0.47 [0.04, 5.03]	
Tarbeeh 2013 1 20 0 20 0.2% 3.00 [0.13, 69.52] Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Image: Chize 18.82, df = 11 (P = 0.06); l ² = 42% Test for overall effect: Z = 1.14 (P = 0.25) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Image: Chize 18.67, df = 37 (P = 0.21); l ² = 15% Image: Chize 18.67, df = 37 (P = 0.200001) Image: Chize 19.67, df = 37 (P = 0.200001) Test for overall effect: Z = 5.37 (P < 0.00001)	Shahi 2014	6	40	4	40	1.7%	1.50 [0.46, 4.91]	
Tekin 2007 0 30 0 30 Not estimable Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Total events 32 42 Heterogeneity: Chi ² = 18.82, df = 11 (P = 0.06); l ² = 42% Test for overall effect: Z = 1.14 (P = 0.25) Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); l ² = 15% 0.01 0.1 1 100 Test for overall effect: Z = 5.37 (P < 0.00001)	Tarbeeh 2013	1	20	0	20	0.2%	3.00 [0.13, 69.52]	
Yektas 2014 5 20 2 20 0.9% 2.50 [0.55, 11.41] Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Total events 32 42 Heterogeneity: Chi ² = 18.82, df = 11 (P = 0.06); l ² = 42% Test for overall effect: Z = 1.14 (P = 0.25) Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); l ² = 15% 0.01 0.1 1 10 100 Test for overall effect: Z = 5.37 (P < 0.00001)	Tekin 2007	0	30	0	30		Not estimable	
Subtotal (95% CI) 466 465 18.4% 0.78 [0.51, 1.19] Total events 32 42 Heterogeneity: Chi ² = 18.82, df = 11 (P = 0.06); l ² = 42% Test for overall effect: Z = 1.14 (P = 0.25) Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); l ² = 15% 0.01 0.1 1 100 Test for overall effect: Z = 5.37 (P < 0.00001)	Yektas 2014	5	20	2	20	0.9%	2.50 [0.55, 11.41]	
Total events 32 42 Heterogeneity: $Chi^2 = 18.82$, $df = 11$ (P = 0.06); $l^2 = 42\%$ Test for overall effect: Z = 1.14 (P = 0.25) Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: $Chi^2 = 43.67$, $df = 37$ (P = 0.21); $l^2 = 15\%$ 0.01 0.1 1 10 100 Test for overall effect: Z = 5.37 (P < 0.00001) Eavours (dexmedetomidine) Eavours (dexmedetomidine) Eavours (dexmedetomidine)	Subtotal (95% CI)		466		465	18.4%	0.78 [0.51, 1.19]	•
Heterogeneity: $Chi^2 = 18.82$, $df = 11 (P = 0.06)$; $l^2 = 42\%$ Test for overall effect: $Z = 1.14 (P = 0.25)$ Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] \bullet Total events 138 228 Heterogeneity: $Chi^2 = 43.67$, $df = 37 (P = 0.21)$; $l^2 = 15\%$ Test for overall effect: $Z = 5.37 (P < 0.00001)$ Test for overall effect: $Z = 5.37 (P < 0.00001)$ Eavours [dexmedetomidine] Eavours [dexmedetomidine]	Total events	32		42				
Test for overall effect: $Z = 1.14$ (P = 0.25) Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); l ² = 15% 0.01 0.1 1 10 100 Test for overall effect: Z = 5.37 (P < 0.00001)	Heterogeneity: Chi ² = 1	18.82, df = 11 (P = 0.06)	; l² = 42%	6			
Total (95% CI) 1248 1238 100.0% 0.61 [0.50, 0.73] Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); l ² = 15% 0.01 0.1 1 10 100 Test for overall effect: Z = 5.37 (P < 0.00001)	Test for overall effect: 2	Z = 1.14 (P = 0	.25)					
Total events 138 228 Heterogeneity: Chi ² = 43.67, df = 37 (P = 0.21); l ² = 15% 0.01 0.1 1 10 100 Test for overall effect: Z = 5.37 (P < 0.00001) Eavours [dexmedetomidine] Eavours [dexmedetomidine]	Total (95% CI)		1248		1238	100.0%	0.61 [0.50 0.73]	◆
Heterogeneity: $Chi^2 = 43.67$, $df = 37$ (P = 0.21); $l^2 = 15\%$ Image: the second seco	Total events	138	.240	228	.200	100.070	0.01 [0.00, 0.70]	•
Test for overall effect: $Z = 5.37$ (P < 0.00001) Eavours [dexmedetomidine] Eavours [dexmedetomidine] Eavours [dexmedetomidine]	Heterogeneity: Chi ² = 4	13.67 df = 37 (P = 0.21	$ ^2 = 15\%$	6			
Eavours [dexmedetomidine] Eavours [nlacebo]	Test for overall effect:	Z = 5.37 (P < 0)	.00001)		-		_	0.01 0.1 1 10 100
Test for subgroup differences: Chi ² = 1.88, df = 1 ($P = 0.17$), $P = 46.7\%$	Test for subaroup diffe	rences: Chi ² =	1.88. df =	= 1 (P = 0	.17). l²	= 46.7%	Fav	ours [dexmedetomidine] Favours [placebo]

Figure 3. Results of subgroup analysis of the incidence of postoperative nausea by anesthesia types.

24, 29, 49]: 0.30, 95% CI: 0.13 to 0.66), laparoscopy (nausea: pooled RR of six trials [22, 27, 35, 46, 49, 55]: 0.40, 95% CI: 0.25 to 0.66; vomiting [22, 35, 49, 51, 55]: pooled RR of five trials: 0.36, 95% CI: 0.15 to 0.87), postopera-

tive opioid treatment (nausea: pooled RR of nine trials [27, 29, 38, 42, 51, 55, 59-61]: 0.50, 95% CI: 0.37 to 0.69; vomiting: pooled RR of five trials [29, 33, 38, 51, 55, 60, 61]: 0.42, 95% CI: 0.25 to 0.70) (**Table 3**).

	Dexmedetom	idine	Placeb	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Fixed, 95% C	M-H, Fixed, 95% Cl
2.1.1 General anesthe	esia				•		
Agarwal 2014	0	25	0	25		Not estimable	
Ali 2013	4	40	3	40	2.8%	1.33 [0.32, 5.58]	
Bakhamees 2007	0	40	0	40		Not estimable	
Bindu 2013	1	25	2	25	1.9%	0.50 [0.05, 5.17]	
Chen 2013	4	27	11	24	10.8%	0.32 [0.12, 0.88]	
Cicek 2006	4	25	6	25	5.6%	0.67 [0.21, 2.08]	
Erdil 2009	1	30	1	30	0.9%	1.00 [0.07, 15.26]	
Guler 2005	11	30	16	30	14.8%	0.69 [0.39, 1.22]	
Kim a 2013	8	25	18	25	16.7%	0.44 [0.24, 0.83]	
Massad 2009	5	42	8	39	7.7%	0.58 [0.21, 1.62]	+
Mizrak 2013	0	30	0	30		Not estimable	
Sato 2010	3	39	3	42	2.7%	1.08 [0.23, 5.02]	
Shin 2013	0	21	0	21		Not estimable	
Singh 2012	1	40	4	40	3.7%	0.25 [0.03, 2.14]	
Tufanogullari 2008	1	20	3	20	2.8%	0.33 [0.04, 2.94]	
Turan 2008	0	20	0	20		Not estimable	
Unlugenc 2005	0	30	0	30		Not estimable	
Wu 2011	0	20	5	20	5.1%	0.09 [0.01, 1.54]	← +
Wu 2013	1	40	4	40	3.7%	0.25 [0.03, 2.14]	
Yildiz 2006	3	25	9	25	8.3%	0.33 [0.10, 1.09]	
Subtotal (95% CI)		594		591	87.4%	0.50 [0.37, 0.68]	◆
Total events	47		93			-	
Heterogeneity: Chi ² = 8	3.14. df = 13 (P	= 0.83):	l² = 0%				
Test for overall effect:	Z = 4.49 (P < 0.	00001)					
	,	,					
2.1.2 Regional anesth	nesia						
Elcicek 2010	0	30	0	30		Not estimable	
Esmaoglu 2013	1	30	1	30	0.9%	1.00 [0.07, 15.26]	
Goksu 2008	3	30	13	32	11.7%	0.25 [0.08, 0.78]	
Gupta a 2011	0	30	0	30		Not estimable	
Mizrak b 2010	0	15	0	15		Not estimable	
Nie 2014	0	40	0	38		Not estimable	
Tarbeeh 2013	0	20	0	20		Not estimable	
Subtotal (95% CI)		195		195	12.6%	0.30 [0.11, 0.85]	
Total events	4		14				
Heterogeneity: Chi ² = (0.86, df = 1 (P =	0.35); 1	² = 0%				
Test for overall effect:	Z = 2.28 (P = 0.	02)					
Total (95% CI)		789		786	100.0%	0.48 [0.36, 0.64]	◆
Total events	51		107				
Heterogeneity: Chi ² = 1	10.02, df = 15 (F	P = 0.82); l² = 0%				
Test for overall effect:	Z = 5.02 (P < 0.	00001)				F.	0.01 0.1 1 10 100
Test for subaroup diffe	rences: Chi ² = ().85. df =	= 1 (P = 0	.36). I²	= 0%	Fa	avours [experimental] Favours [control]

Figure 4. Results of subgroup analysis of the incidence of postoperative vomiting by anesthesia types.

Consumption of intraoperative analgesics: Application of dexmedetomidine reduced the dose of intraoperative fentanyl infused as the only analgesic agent intravenously (pooled SMD of five trails [24, 30, 38, 49, 55, 59]: -1.91, 95% CI: -3.20 to -0.62) compared with placebo. A sensitivity analysis to remove a high-risk study [38] showed a similar result favoring dexmedetomidine (pooled SMD = -2.30, 95% CI: -3.86 to -0.73), but still did not decrease heterogeneity ($l^2 = 95\%$) (**Figure 7**). Dexmedetomidine vs. other agents: Forty-one studies [16, 18, 23, 32, 34, 44, 46, 48, 63-77, 79-96], compared the efficacy of dexmedetomidine with other drugs on nausea and vomiting, involving 2,536 and 1,368 patients in each group. Dexmedetomidine could reduce the incidence of vomiting compared with the total agents (pooled RR of 24 trials [23, 32, 34, 35, 48, 63, 66, 68-70, 75-77, 79-82, 84, 86-88, 90, 92, 96]: 0.28, 95% CI: 0.18 to 0.43), but not nausea (pooled RR of 34 trials [16, 18, 23,

	Dexmedetom	nidine	Place	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
7.1.1 Intravenous							
Abdelmageed 2011	7	20	14	19	6.6%	0.47 [0.25, 0.91]	
Bakhamees 2007	2	40	3	40	1.4%	0.67 [0.12, 3.78]	
Cheung 2011	8	33	4	33	1.8%	2.00 [0.67, 6.00]	
Cicek 2006	8	25	11	25	5.1%	0.73 [0.35, 1.50]	
Dinesh 2014	2	50	0	50	0.2%	5.00 [0.25, 101.58]	
Elcicek 2010	3	30	2	30	0.9%	1.50 [0.27, 8.34]	
Elvan 2008	2	40	2	40	0.9%	1.00 [0.15, 6.76]	
Goksu 2008	5	30	25	32	11.1%	0.21 [0.09, 0.48]	(
Gupta 2013	2	18	9	18	4.1%	0.22 [0.06, 0.89]	
Gurbet 2006	6	25	15	25	6.9%	0.40 [0.19, 0.86]	
Gyanesh 2014	2	52	3	46	1.5%	0.59 [0.10, 3.38]	
Hong 2012	2	26	1	25	0.5%	1.92 [0.19, 19.90]	
lsik 2006	1	21	2	21	0.9%	0.50 [0.05, 5.10]	
Kim a 2013	8	25	5	25	2.3%	1.60 [0.61, 4.22]	
Kim b 2013	18	46	26	46	12.0%	0.69 [0.45, 1.08]	
Lee 2013	1	28	8	29	3.6%	0.13 [0.02, 0.97]	
Massad 2009	8	42	15	39	7.2%	0.50 [0.24, 1.04]	
Mazanikov 2013	2	25	1	25	0.5%	2.00 [0.19, 20.67]	
Mizrak 2013	2	30	3	30	1.4%	0.67 [0.12, 3.71]	
Mizrak a 2010	5	30	8	30	3.7%	0.63 [0.23, 1.69]	
Mizrak b 2010	0	15	0	15		Not estimable	
Nie 2014	1	40	2	38	0.9%	0.47 [0.04, 5.03]	
Ohtani 2011	3	16	2	16	0.9%	1.50 [0.29, 7.81]	<u> </u>
Ozkose 2006	2	20	3	20	1.4%	0.67 [0.12, 3.57]	
Shin 2013	2	21	3	21	1.4%	0.67 [0.12, 3.59]	
Singh 2012	2	40	7	40	3.2%	0.29 [0.06, 1.29]	
Tekin 2007	0	30	0	30		Not estimable	
Tufanogullari 2008	5	20	13	20	6.0%	0.38 [0.17, 0.88]	
Turan 2008	0	20	0	20		Not estimable	
Unlugenc 2005	2	30	4	30	1.8%	0.50 [0.10, 2.53]	
Wu 2011	1	20	6	20	2.8%	0.17 [0.02, 1.26]	
Wu 2013	1	40	5	40	2.3%	0.20 [0.02, 1.64]	
Yildiz 2006	6	25	10	25	4.6%	0.60 [0.26, 1.40]	
Zhao 2014	0	30	4	30	2.1%	0.11 [0.01, 1.98]	· · · · · · · · · · · · · · · · · · ·
Subtotal (95% CI)		1003		993	100.0%	0.55 [0.45, 0.67]	◆
Total events	119		216				
Heterogeneity: Chi ² = 3	33.89. df = 30 (l	P = 0.29); ² = 11%	'n			
Test for overall effect:	Z = 6.09 (P < 0.00)	.00001)	,				
		,					
7.1.2 Epidural							
Jain 2012	0	30	0	30		Not estimable	
Neogi 2010	3	25	1	25	20.0%	3.00 [0.33, 26,92]	
Shahi 2014	6	40	4	40	80.0%	1.50 [0.46, 4.91]	
Subtotal (95% CI)		95		95	100.0%	1.80 [0.64, 5.07]	
Total events	9		5				
Heterogeneity: Chi ² = (0.30, df = 1 (P =	= 0.58); I	² = 0%				
Test for overall effect:	Z = 1.11 (P = 0)	.27)					
		,					
7.1.3 Spinal							
Esmaoglu 2013	2	30	1	30	18.2%	2.00 [0.19. 20.90]	
Gupta a 2011	- 1	30	2	30	36.4%	0.50 [0.05, 5.22]	
Tarbeeh 2013	1	20	0	20	9.1%	3.00 [0.13, 69.52]	
Yektas 2014	5	20	2	20	36.4%	2.50 [0.55, 11.41]	- -
Subtotal (95% CI)	÷	100	-	100	100.0%	1.73 [0.63, 4.71]	
Total events	9		5				
Heterogeneity: Chi ² = '	1.43. df = 3 (P =	= 0.70). I	² = 0%				
Test for overall effect	Z = 1.07 (P = 0)	.29)	0 /0				
						-	0.01 0.1 1 10 100
Test for subgroup diffe		0.07 46.	- 0 (D - 0	000	2 - 70 70/	Fave	ours [dexmedetomdine] Favours [placebo]

Test for subaroup differences: $Chi^2 = 9.37$. df = 2 (P = 0.009). $I^2 = 78.7\%$

Figure 5. Results of subgroup analysis of the incidence of postoperative nausea by routes of dexmedetomidine administration.

44, 46, 63, 65, 67-69, 71-77, 79-83, 85-96]: 0.89, 95% CI: 0.73 to 1.09). Further, the significant difference could be found specifically between dexmedetomidine and opioids (nausea: pooled RR of 16 trials [23, 68, 69, 72, 73, 77, 80-83, 86, 87, 91, 93, 95, 96]: 0.75, 95% CI:

	Dexmedetom	idine	Placeb	0		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
8.1.1 Intravenous							
Ali 2013	4	40	3	40	2.8%	1.33 [0.32, 5.58]	
Bakhamees 2007	0	40	0	40		Not estimable	
Bindu 2013	1	25	2	25	1.9%	0.50 [0.05, 5.17]	
Chen 2013	4	27	11	24	10.9%	0.32 [0.12, 0.88]	
Cicek 2006	4	25	6	25	5.6%	0.67 [0.21, 2.08]	
Elcicek 2010	0	30	0	30		Not estimable	
Erdil 2009	1	30	1	30	0.9%	1.00 [0.07, 15.26]	
Goksu 2008	3	30	13	32	11.8%	0.25 [0.08, 0.78]	
Guler 2005	11	30	16	30	15.0%	0.69 [0.39, 1.22]	
Kim a 2013	8	25	18	25	16.8%	0.44 [0.24, 0.83]	
Massad 2009	5	42	8	39	7.8%	0.58 [0.21, 1.62]	
Mizrak 2013	0	30	0	30		Not estimable	
Mizrak b 2010	0	15	0	15		Not estimable	
Nie 2014	0	40	0	38		Not estimable	
Sato 2010	3	39	3	42	2.7%	1.08 [0.23, 5.02]	
Shin 2013	0	21	0	21		Not estimable	
Singh 2012	1	40	4	40	3.7%	0.25 [0.03, 2.14]	
Tufanogullari 2008	1	20	3	20	2.8%	0.33 [0.04, 2.94]	
Turan 2008	0	20	0	20		Not estimable	
Unlugenc 2005	0	30	0	30		Not estimable	
Wu 2011	0	20	5	20	5.1%	0.09 [0.01, 1.54]	· · · · · · · · · · · · · · · · · · ·
Wu 2013	1	40	4	40	3.7%	0.25 [0.03, 2.14]	
Yildiz 2006	3	25	9	25	8.4%	0.33 [0.10, 1.09]	
Subtotal (95% CI)		684		681	100.0%	0.47 [0.35, 0.63]	◆
Total events	50		106				
Heterogeneity: Chi ² = 9	.79, df = 14 (P	= 0.78); I	² = 0%				
Test for overall effect: 2	z = 5.06 (P < 0.	00001)					
9 4 2 Cainal							
6.1.5 Spinar				~~	400.00/	4 00 10 07 45 00	
Esmaogiu 2013	1	30	1	30	100.0%	1.00 [0.07, 15.26]	—
Gupta a 2011	0	30	0	30		Not estimable	
Subtotal (95% CI)	0	20	0	20	100.0%	1 00 00 7 15 261	
Total ovente	1	00	1	00	100.070	1.00 [0.07, 10.20]	
Hotorogonoity: Not one	licabla						
Test for overall offect:	7 = 0.00 (P = 1)	00)					
rescior overall effect: 2	- 0.00 (F = 1.	00)					
							0.01 0.1 1 10 100
Test for subaroup diffe	ences: Chi ² = 0	.29. df =	1 (P = 0.	59). I²	= 0%	Fav	ours [dexmedetomidine] Favours [placebo]

Figure 6. Results of subgroup analysis of the incidence of postoperative vomiting by routes of dexmedetomidine administration.

	Dexmedetomidine			Placebo				Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV. Random. 95% CI
Bakhamees 2007	199.4	44.6	40	362.2	57.2	40	20.2%	-3.14 [-3.81, -2.48]	
Gupta 2013	2.3	0.5	18	3.1	0.6	18	19.9%	-1.42 [-2.16, -0.68]	
Gurbet 2006	255	16	25	325	17	25	18.8%	-4.17 [-5.19, -3.16]	
Massad 2009	112.8	51.3	42	145.86	57.1	39	20.8%	-0.60 [-1.05, -0.16]	
Wu 2011	4.9	0.8	20	5.2	0.7	20	20.3%	-0.39 [-1.02, 0.24]	
Total (95% CI)			145			142	100.0%	-1.91 [-3.20, -0.62]	•
Heterogeneity: Tau ² = 2.03; Chi ² = 77.21, df = 4 (P < 0.00001); l ² = 95 ⁶							%	-	
Test for overall effect: Z = 2.90 (P = 0.004) Favours [dexn							-4 -2 0 2 4 urs [dexmedetomidine] Favours [placebo]		

Figure 7. Consumption of intraoperative fentanyl with the application of dexmedetomidine.

0.56 to 0.99; vomiting: pooled RR of 12 trials [23, 48, 68, 69, 77, 80-82, 84, 86, 87, 96]: 0.22, 95% Cl: 0.12 to 0.41), but not sedation agents (nausea: pooled RR of ten trials [63, 65, 67, 74, 76, 85, 88-90, 94]: 1.08, 95% Cl: 0.75 to 1.54; vomiting: pooled RR of seven trials [34, 63, 66, 70, 76, 88, 90]: 0.57, 95% Cl: 0.26 to

1.23) (Table 4).

Sensitivity analysis: Upon the studies with high risk were excluded by sensitivity analysis, there was no significant difference in results from overall pooled estimates across all outcomes above.

Comparison	Number of studies	dexmedetomi- dine	agents	RR (95% CI)	 ²	References
nausea	34	145/1275	162/1261	0.89 (0.73, 1.09)	20%	[16, 18, 23, 44, 46, 63, 65, 67-69, 71-77, 79-83, 85-96]
opioids	16	66/537	89/536	0.75 (0.56, 0.99)	40%	[23, 68, 69, 72, 73, 77, 80-83, 86, 87, 91, 93, 95, 96]
fentanyl	8	23/217	39/222	0.61 (0.40, 0.94)	29%	[23, 68, 73, 80, 86, 87, 93, 96]
remifentanil	4	16/86	18/86	0.89 (0.50, 1.60)	45%	[77, 82, 91, 95]
morphine	4	27/234	32/228	0.83 (0.52, 1.33)	51%	[69, 72, 81, 83]
sedation agents	10	55/490	50/477	1.08 (0.75, 1.54)	0%	[63, 65, 67, 74, 76, 85, 88-90, 94]
propofol	4	28/238	28/235	0.99 (0.61, 1.61)	0%	[63, 67, 88, 94]
midazolam	6	27/252	22/242	1.19 (0.70, 2.03)	0%	[65, 74, 76, 85], 86], 89], 90]
vomiting	24	23/687	82/681	0.28 (0.18, 0.43)	0%	[23, 32, 34, 35, 48, 63, 66, 68-70, 75-77, 79-82, 84, 86-88, 90], 92], 96]
opioids	12	11/340	48/339	0.27 (0.15, 0.47)	0%	[23, 48, 68, 69, 77, 80-82, 84, 86, 87, 96]
fentanyl	7	7/203	25/203	0.25 (0.11, 0.59)	0%	[23, 48, 68, 80, 86, 87, 96]
remifentanil	3	1/80	13/80	0.12 (0.03, 0.55)	0%	[77, 82, 84]
morphine	2	3/57	10/56	0.27 (0.07, 1.00)	0%	[69, 81]
sedation agents	7	8/216	15/211	0.57 (0.26, 1.23)	0%	[34, 63, 66, 70, 76, 88, 90]
propofol	4	6/139	9/137	0.67 (0.25, 1.84)	0%	[34, 63, 70, 88]
midazolam	3	2/77	6/74	0.35 (0.08, 1.61)	0%	[66, 76, 90]

Table 4. Efficacy of dexmedetomidine on reducing nausea and vomiting compared with other agents

Discussion

PONV is a long-standing problem, not a new concept in anesthesiology. Despite plenty of studies over the past few decades, PONV remains an extremely significant challenge due to its complex mechanism, resulting in serious consequences. Therefore an effective way to prevent or arrest PONV is urgently needed as ever.

The present meta-analysis was undertaken to evaluate the efficacy of dexmedetomidine on the prevention of nausea and vomiting. The main findings are as follows: (1) Dexmedetomidine shows superiority to placebo, in the prevention of nausea and vomiting with highrisk factors or not, and opioids, but not to sedation agents. (2) The beneficial effect of dexmedetomidine on nausea and vomiting can be achieved through intravenous injection only, with common timing of administration and dosage regimen. (3) As the most commonly used dose in published articles, intravenous 0.5 µg/ kg bolus infusion has a preventive effect on nausea, while 1.0 µg/kg bolus infusion reduces the indication of vomiting. (4) Using of dexmedetomidine reduces the total intraoperative consumption of analgesic agents.

This beneficial antiemetic effect may be explained by direct antiemetic properties of α_2 agonists, although the biologic basis remains obscure. Additionally, since nausea and vomiting may be induced by high catecholamine concentrations, a decrease of sympathetic tone could explain the antiemetic effect of dexmedetomidine. Finally, consumption of intraoperative opioids, which increases the risk of PONV [97], may be reduced through the use of dexmedetomidine.

Controversy existed in previous meta-analysis about the efficacy on nausea and vomiting, several studies [22, 98, 99] suggested an absolutely superior role of dexmedetomidine compared with placebo, but the others [100-102] not. However, only analyzing nine trails at most, these results might be equivocal relatively. And dexmedetomidine was also not compared with other agents directly. In contrast, we included 82 articles with vast clinical outcome variables to improve the reliability of our conclusion.

To the best of our knowledge, this is the first time to shed light on the efficacy of dexmedeto-

midine on nausea and vomiting from a variety of aspects, by a meta-analysis of RCTs. The majority of included trials were well designed and assessed as "Low". Moreover, we directly compared dexmedetomidine with opioid analgesics and sedation agents, meanwhile eliminated studies with high risk by sensitivity analysis. All of these strategies were administrated to come up with a solid conclusion.

The clinical usage of dexmedetomidine to prevent nausea and vomiting is still unascertained. So in this meta-analysis, we newly found that 0.5 µg/kg bolus infusion was sufficiently effective to prevent nausea, and 1.0 µg/kg dexmedetomidine only reduces the occurrence of vomiting, interestingly. Our result that only intravenous dexmedetomidine, not epidural or spinal, was an available option for antiemetic might cause confusion, since regional administration has always been used widely as a fast and cheap way. We speculate that high hydrophobic may be responsible. Dexmedetomidine might decrease the noradrenergic activity as a result of binding to α_2 presynaptic inhibitory adrenoreceptor in the locus coeruleus, an inhibition that probably resulted in an antiemetic effect [103]. But only about 22% of the epidural dose was identified in cerebrospinal fluid, the other dose was distributed into epidural fat. And as a highly hydrophobic agent, dexmedetomidine could non-specifically bind to spinal cord white matter that limited dexmedetomidine to transferring towards the pontine brain stem [104], which possibly cut off potential antiemetic pathway mentioned above. Therefore, even extradural 1-2 µg/kg or subarachnoid 3-5 µg dexmedetomidine mentioned in the included trials may not be enough to reach the plasma concentration activating the receptors which may inhibit PONV compared with at least 0.3 μ g/kg intravenously.

Still, this meta-analysis has several limitations. First, the total number of trails included is significant relatively, but the amounts in some subgroups, like dose, epidural or spinal infuse, consumption of intraoperative fentanyl subgroups etc., is still too little to secure the conclusive results. Second, only 32 trials reported the source of their funding, however we did not know whether or not the others were supported by companies or industries, which may incline the design towards the best light of drug. Third, the high risk factors of PONV, like prior history of motion sickness and/or PONV and nonsmoker, were so difficult to detect throughout the literature that we failed to include these as the evaluation items. Forth, the significant heterogeneity in analgesic consumption subgroup, due to the different types and lengths of surgeries probably, still exists after lots of efforts. Therefore, more RCTs, including kinds of patients and various doses or routes of administration in specific surgeries or anesthesia, should be designed reasonably to detect the efficacy of dexmedetomidine on PONV.

In conclusion, our present meta-analysis demonstrated that the intravenous infusion of dexmedetomidine may reduce the incidence of PONV, compared with placebo and opioids, rather than sedatives, which is due to the reduced consumption of intraoperative opioids probably. The results may provide a new evidence to expand the clinical value of dexmedetomidine in addition to its routine usage for analgesia and sedation.

Acknowledgements

This study was supported by the funds from Shanghai Municipal Science and Technology Commission (12ZR1439400) and Shanghai Municipal Bureau of Health Fund (201243423).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Xin Lv, Department of Anesthesiology, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, No. 507, Zhengmin Road, Shanghai 200433, China. Tel: 86-21-65115006; Fax: 86-021-65115006; E-mail: xinlvg@126.com; Dr. Peng-Cheng Ren, Tangdu Hospital, The Fourth Military Medical University, No. 1 Xinsi Road, Xi'an 710038, Shanxi Province, China. Tel: 86-29-84717318; Fax: 86-029-84717337; E-mail: tdrpch@163.com

References

- Watcha MF and White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162-184.
- [2] Rashiq S and Bray P. Relative value to surgical patients and anesthesia providers of selected anesthesia related outcomes. BMC Med Inform Decis Mak 2003; 3: 3.

- [3] Watcha MF and White PF. New antiemetic drugs. Int Anesthesiol Clin 1995; 33: 1-20.
- [4] Gan TJ. Postoperative nausea and vomitingcan it be eliminated? JAMA 2002; 287: 1233-1236.
- [5] Apfel CC, Laara E, Koivuranta M, Greim CA and Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91: 693-700.
- [6] Wu HH, Wang HT, Jin JJ, Cui GB, Zhou KC, Chen Y, Chen GZ, Dong YL and Wang W. Does dexmedetomidine as a neuraxial adjuvant facilitate better anesthesia and analgesia? A systematic review and meta-analysis. PLoS One 2014; 9: e93114.
- [7] Sun Y, Lu Y, Huang Y and Jiang H. Is dexmedetomidine superior to midazolam as a premedication in children? A meta-analysis of randomized controlled trials. Paediatr Anaesth 2014; 24: 863-874.
- [8] Hoy SM and Keating GM. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs 2011; 71: 1481-1501.
- [9] Apfel CC, Roewer N and Korttila K. How to study postoperative nausea and vomiting. Acta Anaesthesiol Scand 2002; 46: 921-928.
- [10] Visser K, Hassink EA, Bonsel GJ, Moen J and Kalkman CJ. Randomized controlled trial of total intravenous anesthesia with propofol versus inhalation anesthesia with isoflurane-nitrous oxide: postoperative nausea with vomiting and economic analysis. Anesthesiology 2001; 95: 616-626.
- [11] Higgins JPT, Green S; Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester, England; Hoboken, NJ: Wiley-Blackwell; 2008. pp. 649.
- [12] Elkassem SA. Dexmedetomidine VS remifentanil in abdominoplasty surgery (BIS guided): A comparative study. Egypt J Anaesth 2008; 24: 261-269.
- [13] Wellisch OM, Kronenfeld M, Saberito D, Pagala M, Choueka J and Gupta P. A prospective randomized controlled trial comparing the efficacy and safety of dexmedetomidine versus propofol tiva in conjunction with regional block for shoulder surgery in beach chair sitting position. Reg Anesth Pain Med 2012; 37.
- [14] Zhao X, Tong D, Long B and Wu X. [Effects of different doses of dexmedetomidine on the recovery quality from general anesthesia undergoing thyroidectomy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2014; 26: 239-243.
- [15] Yektas A and Belli E. The effects of 2 µg and 4 µg doses of dexmedetomidine in combination

with intrathecal hyperbaric bupivacaine on spinal anesthesia and its postoperative analgesic characteristics. Pain Res Manag 2014; 19: 75-81.

- [16] Shahi V, Verma AK, Agarwal A and Singh CS. A comparative study of magnesium sulfate vs dexmedetomidine as an adjunct to epidural bupivacaine. J Anaesthesiol Clin Pharmacol 2014; 30: 538-542.
- [17] Nie Y, Liu Y, Luo Q and Huang S. Effect of dexmedetomidine combined with sufentanil for post-caesarean section intravenous analgesia: A randomised, placebo-controlled study. Eur J Anaesthesiol 2014; 31: 197-203.
- [18] Gyanesh P, Haldar R, Srivastava D, Agrawal PM, Tiwari AK and Singh PK. Comparison between intranasal dexmedetomidine and intranasal ketamine as premedication for procedural sedation in children undergoing MRI: A double-blind, randomized, placebo-controlled trial. J Anesth 2014; 28: 12-18.
- [19] Dinesh CN, Sai Tej NA, Yatish B, Pujari VS, Mohan Kumar RM and Mohan CVR. Effects of intravenous dexmedetomidine on hyperbaric bupivacaine spinal anesthesia: A randomized study. Saudi J Anaesth 2014; 8: 202-208.
- [20] Almarakbi W and Kaki A. Addition of dexmedetomidine to bupivacaine in transversus abdominis plane block potentiates post-operative pain relief among abdominal hysterectomy patients: A prospective randomized controlled trial. Saudi J Anaesth 2014; 8: 161-166.
- [21] Agarwal S, Aggarwal R and Gupta P. Dexmedetomidine prolongs the effect of bupivacaine in supraclavicular brachial plexus block. J Anaesthesiol Clin Pharmacol 2014; 30: 36-40.
- [22] Wu Y, Huang H, Zeng J, Li B, Lei X and Chen Y. [Effect of dexmedetomidine in preventing shivering after general anesthesia for laparoscopic surgery: a randomized, single-blinded, and placebo-controlled trial]. Nan Fang Yi Ke Da Xue Xue Bao 2013; 33: 611-614.
- [23] Tarbeeh GA and Mohamed AA. Effects of intrathecal bupivacaine-fentanyl versus bupivacaine- dexmedetomidine in diabetic surgical patients. Egypt J Anaesth 2013; 29: 13-18.
- [24] Shin HW, Yoo HN, Kim DH, Lee H, Shin HJ and Lee HW. Preanesthetic dexmedetomidine 1 μ g/kg single infusion is a simple, easy, and economic adjuvant for general anesthesia. Korean J Anesthesiol 2013; 65: 114-120.
- [25] Mizrak A, Karatas E, Saruhan R, Kara F, Oner U, Saricicek V and Baysal E. Does dexmedetomidine affect intraoperative blood loss and clotting tests in pediatric adenotonsillectomy patients? J Surg Res 2013; 179: 94-98.
- [26] Mazanikov M, Udd M, Kylanpaa L, Mustonen H, Lindstrom O, Halttunen J and Poyhia R. Dexmedetomidine impairs success of patientcontrolled sedation in alcoholics during ERCP:

A randomized, double-blind, placebo-controlled study. Surg Endosc 2013; 27: 2163-2168.

- [27] Lee C, Kim YD and Kim JN. Antihyperalgesic effects of dexmedetomidine on high-dose remifentanil-induced hyperalgesia. Korean J Anesthesiol 2013; 64: 301-307.
- [28] Kim b SH, Oh YJ, Park BW, Sim J and Choi YS. Effects of single-dose dexmedetomidine on the quality of recovery after modified radical mastectomy: A randomised controlled trial. Minerva Anestesiol 2013; 79: 1248-1258.
- [29] Kim a SY, Chang CH, Lee JS, Kim YJ, Kim MD and Han DW. Comparison of the efficacy of dexmedetomidine plus fentanyl patient-controlled analgesia with fentanyl patient-controlled analgesia for pain control in uterine artery embolization for symptomatic fibroid tumors or adenomyosis: a prospective, randomized study. J Vasc Interv Radiol 2013; 24: 779-786.
- [30] Gupta N, Rath GP, Prabhakar H and Dash HH. Effect of intraoperative dexmedetomidine on postoperative recovery profile of children undergoing surgery for spinal dysraphism. J Neurosurg Anesthesiol 2013; 25: 271-278.
- [31] Esmaoglu A, Turk S, Bayram A, Akin A, Ugur F and Ulgey A. The effects of dexmedetomidine added to spinal levobupivacaine for transurethral endoscopic surgery. Balkan Med J 2013; 30: 186-190.
- [32] Chen JY, Jia JE, Liu TJ, Qin MJ and Li WX. Comparison of the effects of dexmedetomidine, ketamine, and placebo on emergence agitation after strabismus surgery in children. Can J Anaesth 2013; 60: 385-392.
- [33] Bindu B, Pasupuleti S, Gowd UP, Gorre V, Murthy RR and Laxmi MB. A double blind, randomized, controlled trial to study the effect of dexmedetomidine on hemodynamic and recovery responses during tracheal extubation. J Anaesthesiol Clin Pharmacol 2013; 29: 162-167.
- [34] Ali MA and Abdellatif AA. Prevention of sevoflurane related emergence agitation in children undergoing adenotonsillectomy: A comparison of dexmedetomidine and propofol. Saudi J Anaesth 2013; 7: 296-300.
- [35] Bajwa SJ, Gupta S, Kaur J, Singh A and Parmar S. Reduction in the incidence of shivering with perioperative dexmedetomidine: A randomized prospective study. J Anaesthesiol Clin Pharmacol 2012; 28: 86-91.
- [36] Jain D, Khan RM, Kumar D and Kumar N. Perioperative effect of epidural dexmedetomidine with intrathecal bupivacaine on haemodynamic parameters and quality of analgesia. S Afr J Anaesth Analg 2012; 18: 105-109.
- [37] Hong JY, Kim WO, Yoon Y, Choi Y, Kim SH and Kil HK. Effects of intravenous dexmedetomidine on low-dose bupivacaine spinal anaesthe-

sia in elderly patients. Acta Anaesthesiol Scand 2012; 56: 382-387.

- [38] Wu ZL, Zhou ZF, Xu LX and She SZ. [Effect of dexmedetomidine on patient-controlled intravenous analgesia with fentanyl in elderly patients after total hip replacement]. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31: 701-704.
- [39] Ohtani N, Yasui Y, Watanabe D, Kitamura M, Shoji K and Masaki E. Perioperative infusion of dexmedetomidine at a high dose reduces postoperative analgesic requirements: A randomized control trial. J Anesth 2011; 25: 872-878.
- [40] Gupta R, Bogra J, Verma R, Kohli M, Kushwaha JK and Kumar S. Dexmedetomidine as an intrathecal adjuvant for postoperative analgesia. Indian J Anaesth 2011; 55: 347-351.
- [41] Cheung CW, Jacobus Ng KF, Choi WS, Chiu WK, Aaron Ying CL and Irwin MG. Evaluation of the analgesic efficacy of local dexmedetomidine application. Clin J Pain 2011; 27: 377-382.
- [42] Abdelmageed WM, Elquesny KM, Shabana RI, Abushama HM and Nassar AM. Analgesic properties of a dexmedetomidine infusion after uvulopalatopharyngoplasty in patients with obstructive sleep apnea. Saudi J Anaesth 2011; 5: 150-156.
- [43] Sato M, Shirakami G, Tazuke-Nishimura M, Matsuura S, Tanimoto K and Fukuda K. Effect of single-dose dexmedetomidine on emergence agitation and recovery profiles after sevoflurane anesthesia in pediatric ambulatory surgery. J Anesth 2010; 24: 675-682.
- [44] Neogi M, Bhattacharjee DP, Dawn S and Chatterjee N. A comparative study between clonidine and dexmedetomidine used as adjuncts to ropivacaine for caudal analgesia in paediatric patients. J Anaesth Clin Pharmacol 2010; 26: 149-153.
- [45] Mizrak A, Gul R, Erkutlu I, Alptekin M and Oner U. Premedication with dexmedetomidine alone or together with 0.5% lidocaine for IVRA. J Surg Res 2010; 164: 242-247.
- [46] Mizrak A, Koruk S, Bilgi M, Kocamer B, Erkutlu I, Ganidagli S and Oner U. Pretreatment with Dexmedetomidine or Thiopental Decreases Myoclonus after Etomidate: A Randomized, Double-Blind Controlled Trial. J Surg Res 2010; 159: e11-e16.
- [47] Elcicek K, Tekin M and Kati I. The effects of intravenous dexmedetomidine on spinal hyperbaric ropivacaine anesthesia. J Anesth 2010; 24: 544-548.
- [48] Erdil F, Demirbilek S, Begec Z, Ozturk E, Ulger MH and Ersoy MO. The effects of dexmedetomidine and fentanyl on emergence characteristics after adenoidectomy in children. Anaesth Intensive Care 2009; 37: 571-576.
- [49] Massad IM, Mohsen WA, Basha AS, Al-Zaben KR, Al-Mustafa MM and Alghanem SM. A balanced anesthesia with dexmedetomidine de-

creases postoperative nausea and vomiting after laparoscopic surgery. Saudi Med J 2009; 30: 1537-1541.

- [50] Turan G, Ozgultekin A, Turan C, Dincer E and Yuksel G. Advantageous effects of dexmedetomidine on haemodynamic and recovery responses during extubation for intracranial surgery. Eur J Anaesthesiol 2008; 25: 816-820.
- [51] Tufanogullari B, White PF, Peixoto MP, Kianpour D, Lacour T, Griffin J, Skrivanek G, Macaluso A, Shah M and Provost DA. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. Anesth Analg 2008; 106: 1741-1748.
- [52] Goksu S, Arik H, Demiryurek S, Mumbuc S, Oner U and Demiryurek AT. Effects of dexmedetomidine infusion in patients undergoing functional endoscopic sinus surgery under local anaesthesia. Eur J Anaesthesiol 2008; 25: 22-28.
- [53] Elvan EG, Oc B, Uzun S, Karabulut E, Coskun F and Aypar U. Dexmedetomidine and postoperative shivering in patients undergoing elective abdominal hysterectomy. Eur J Anaesthesiol 2008; 25: 357-364.
- [54] Tekin M, Kati I, Tomak Y and Kisli E. Effect of Dexmedetomidine Iv on the Duration of Spinal Anesthesia with Prilocaine: A Double-Blind, Prospective Study in Adult Surgical Patients. Curr Ther Res Clin Exp 2007; 68: 313-324.
- [55] Bakhamees HS, El-Halafawy YM, El-Kerdawy HM, Gouda NM and Altemyatt S. Effects of dexmedetomidine in morbidly obese patients undergoing laparoscopic gastric bypass. Middle East J Anaesthesiol 2007; 19: 537-551.
- [56] Yildiz M, Tavlan A, Tuncer S, Reisli R, Yosunkaya A and Otelcioglu S. Effect of dexmedetomidine on haemodynamic responses to laryngoscopy and intubation: Perioperative haemodynamics and anaesthetic requirements. Drugs R D 2006; 7: 43-52.
- [57] Ozkose Z, Demir FS, Pampal K and Yardim S. Hemodynamic and anesthetic advantages of dexmedetomidine, an (alpha)2-agonist, for surgery in prone position. Tohoku J Exp Med 2006; 210: 153-160.
- [58] Isik B, Arslan M, Tunga AD and Kurtipek O. Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery. Paediatr Anaesth 2006; 16: 748-753.
- [59] Gurbet A, Basagan-Mogol E, Turker G, Ugun F, Kaya FN and Ozcan B. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements. Can J Anaesth 2006; 53: 646-652.
- [60] Cicek M, Yucel A, Gedik E, Sagir O, But AK and Ersoy MO. The effects of intra-operative lowdose dexmedetomidine infusion on postoperative pain in patients undergoing septorhinoplasty. Pain Clin 2006; 18: 395-402.

- [61] Unlugenc H, Gunduz M, Guler T, Yagmur O and Isik G. The effect of pre-anaesthetic administration of intravenous dexmedetomidine on postoperative pain in patients receiving patient-controlled morphine. Eur J Anaesthesiol 2005; 22: 386-391.
- [62] Guler G, Akin A, Tosun Z, Ors S, Esmaoglu A and Boyaci A. Single-dose dexmedetomidine reduces agitation and provides smooth extubation after pediatric adenotonsillectomy. Paediatr Anaesth 2005; 15: 762-766.
- [63] Verma R, Gupta R, Bhatia VK, Bogra J and Agarwal SP. Dexmedetomidine and propofol for monitored anesthesia care in the middle ear surgery. Indian J Otol 2014; 20: 70-74.
- [64] Singh C, Pandey RK, Saksena AK and Chandra G. A comparative evaluation of analgo-sedative effects of oral dexmedetomidine and ketamine: A triple-blind, randomized study. Paediatr Anaesth 2014; 24: 1252-1259.
- [65] Sheta SA, Al-Sarheed MA and Abdelhalim AA. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: A double-blinded randomized controlled trial. Paediatr Anaesth 2014; 24: 181-189.
- [66] Sethi P, Mohammed S, Bhatia PK and Gupta N. Dexmedetomidine versus midazolam for conscious sedation in endoscopic retrograde cholangiopancreatography: An open-label randomised controlled trial. Indian J Anaesth 2014; 58: 18-24.
- [67] Peng K, Li J, Ji FH and Li Z. Dexmedetomidine compared with propofol for pediatric sedation during cerebral angiography. J Res Med Sci 2014; 19: 549-555.
- [68] Manuar MB, Majumdar S, Das A, Hajra BK, Dutta S, Mukherjee D, Mitra T and Kundu R. Pain relief after Arthroscopic Knee Surgery: A comparison of intra-articular ropivacaine, fentanyl, and dexmedetomidine: A prospective, double-blinded, randomized controlled study. Saudi J Anaesth 2014; 8: 233-237.
- [69] Kamal MM and Talaat SM. Comparative study of epidural morphine and epidural dexmedetomidine used as adjuvant to levobupivacaine in major abdominal surgery. Egypt J Anaesth 2014; 30: 137-141.
- [70] Hasanin AS and Sira AM. Dexmedetomidine versus propofol for sedation during gastrointestinal endoscopy in pediatric patients. Egypt J Anaesth 2014; 30: 21-26.
- [71] Gupta M, Shailaja S and Sudhir Hegde K. Comparison of intrathecal dexmedetomidine with buprenorphine as adjuvant to bupivacaine in spinal asnaesthesia. J Clin and Diagn Res 2014; 8: 114-117.
- [72] El Shamaa HA and Ibrahim M. A comparative study of the effect of caudal dexmedetomidine versus morphine added to bupivacaine in pedi-

atric infra-umbilical surgery. Saudi J Anaesth 2014; 8: 155-160.

- [73] Techanivate A, Dusitkasem S and Anuwattanavit C. Dexmedetomidine compare with fentanyl for postoperative analgesia in outpatient gynecologic laparoscopy: A randomized controlled trial. J Med Assoc of Thail 2012; 95: 383-390.
- [74] Wan LJ, Huang QQ, Yue JX, Lin L and Li SH. [Comparison of sedative effect of dexmedetomidine and midazolam for post-operative patients undergoing mechanical ventilation in surgical intensive care unit]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2011; 23: 543-546.
- [75] Nasr DA, Omran HA, Hakim SM and Mansour WA. Ultra-rapid opiate detoxification using dexmedetomidine under general anesthesia. J Opioid Manag 2011; 7: 337-344.
- [76] Mountain BW, Smithson L, Cramolini M, Wyatt TH and Newman M. Dexmedetomidine as a pediatric anesthetic premedication to reduce anxiety and to deter emergence delirium. AANA J 2011; 79: 219-224.
- [77] Jung HS, Joo JD, Jeon YS, Lee JA, Kim DW, In JH, Rhee HY and Choi JW. Comparison of an intraoperative infusion of dexmedetomidine or remifentanil on perioperative haemodynamics, hypnosis and sedation, and postoperative pain control. J Int Med Res 2011; 39: 1890-1899.
- [78] Gupta R, Verma R, Bogra J, Kohli M, Raman R and Kushwaha JK. A comparative study of intrathecal dexmedetomidine and fentanyl as adjuvants to bupivacaine. J Anaesthesiol Clin Pharmacol 2011; 27: 339-343.
- [79] Bajwa SJ, Arora V, Kaur J, Singh A and Parmar SS. Comparative evaluation of dexmedetomidine and fentanyl for epidural analgesia in lower limb orthopedic surgeries. Saudi J Anaesth 2011; 5: 365-370.
- [80] Bajwa SJ, Bajwa SK, Kaur J, Singh G, Arora V, Gupta S, Kulshrestha A, Singh A, Parmar SS, Singh A and Goraya S. Dexmedetomidine and clonidine in epidural anaesthesia: A comparative evaluation. Indian J Anaesth 2011; 55: 116-121.
- [81] Olutoye OA, Glover CD, Diefenderfer JW, McGilberry M, Wyatt MM, Larrier DR, Friedman EM and Watcha MF. The effect of intraoperative dexmedetomidine on postoperative analgesia and sedation in pediatric patients undergoing tonsillectomy and adenoidectomy. Anesth Analg 2010; 111: 490-495.
- [82] Turgut N, Turkmen A, Ali A and Altan A. Remifentanil-propofol vs dexmedetomidine -propofol--anesthesia for supratentorial craniotomy. Middle East J Anaesthesiol 2009; 20: 63-70.
- [83] Shehabi Y, Grant P, Wolfenden H, Hammond N, Bass F, Campbell M and Chen J. Prevalence of delirium with dexmedetomidine compared

with morphine based therapy after cardiac surgery: A randomized controlled trial (DEXmedetomidine compared to morphine-DEXCOM study). Anesthesiology 2009; 111: 1075-1084.

- [84] Salman N, Uzun S, Coskun F, Salman MA, Salman AE and Aypar U. Dexmedetomidine as a substitute for remifentanil in ambulatory gynecologic laparoscopic surgery. Saudi Med J 2009; 30: 77-81.
- [85] Rutkowska K, Knapik P and Misiolek H. The effect of dexmedetomidine sedation on brachial plexus block in patients with end-stage renal disease. Eur J Anaesthesiol 2009; 26: 851-855.
- [86] Aksu R, Akin A, Bicer C, Esmaoglu A, Tosun Z and Boyaci A. Comparison of the effects of dexmedetomidine versus fentanyl on airway reflexes and hemodynamic responses to tracheal extubation during rhinoplasty: A doubleblind, randomized, controlled study. Curr Ther Res Clin Exp 2009; 70: 209-220.
- [87] Turgut N, Turkmen A, Gökkaya S, Altan A and Hatiboglu MA. Dexmedetomidine -based versus fentanyl-based total intravenous anesthesia for lumbar laminectomy. Minerva Anestesiol 2008; 74: 469-474.
- [88] Kaygusuz K, Gokce G, Gursoy S, Ayan S, Mimaroglu C and Gultekin Y. A comparison of sedation with dexmedetomidine or propofol during shockwave lithotripsy: a randomized controlled trial. Anesth Analg 2008; 106: 114-119.
- [89] Karaaslan K, Yilmaz F, Gulcu N, Colak C, Sereflican M and Kocoglu H. Comparison of dexmedetomidine and midazolam for monitored anesthesia care combined with tramadol via patient-controlled analgesia in endoscopic nasal surgery: A prospective, randomized, double-blind, clinical study. Curr Ther Res Clin Exp 2007; 68: 69-81.
- [90] Demiraran Y, Korkut E, Tamer A, Yorulmaz I, Kocaman B, Sezen G and Akcan Y. The comparison of dexmedetomidine and midazolam used for sedation of patients during upper endoscopy: A prospective, randomized study. Can J Gastroenterol 2007; 21: 25-29.
- [91] Bulow NM, Barbosa NV and Rocha JB. Opioid consumption in total intravenous anesthesia is reduced with dexmedetomidine: a comparative study with remifentanil in gynecologic videolaparoscopic surgery. J Clin Anesth 2007; 19: 280-285.
- [92] Kanazi GE, Aouad MT, Jabbour-Khoury SI, Al Jazzar MD, Alameddine MM, Al-Yaman R, Bulbul M and Baraka AS. Effect of low-dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block. Acta Anaesthesiologica Scandinavica 2006; 50: 222-227.

- [93] Jalowiecki P, Rudner R, Gonciarz M, Kawecki P, Petelenz M and Dziurdzik P. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology 2005; 103: 269-273.
- [94] Herr DL, Sum-Ping STJ and England M. ICU Sedation After Coronary Artery Bypass Graft Surgery: Dexmedetomidine-Based Versus Propofol-Based Sedation Regimens. J Cardiothorac Vasc Anesth 2003; 17: 576-584.
- [95] Chaves TP, Gomes JM, Pereira FE, Cavalcante SL, Leitao IM, Monte HS, Escalante RD. Hemodynamic and metabolic evaluation of dexmedetomidine and remifentanil continuous infusion in videolaparoscopic cholecystectomy. Comparative study. Rev Bras Anestesiol 2003; 53: 419-430.
- [96] Gupta Rb, Verma R, Bogra J, Kohli M, Raman R and Kushwaha JK. A comparative study of intrathecal dexmedetomidine and fentanyl as adjuvants to bupivacaine. J Anaesthesiol Clin Pharmacol 2011; 27: 339-343.
- [97] Smith I, Walley G and Bridgman S. Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery. Eur J Anaesthesiol 2008; 25: 790-799.
- [98] Zhang C, Hu J, Liu X and Yan J. Effects of intravenous dexmedetomidine on emergence agitation in children under sevoflurane anesthesia: a meta-analysis of randomized controlled trials. PLoS One 2014; 9: e99718.
- [99] Piao G and Wu J. Systematic assessment of dexmedetomidine as an anesthetic agent: a meta-analysis of randomized controlled trials. Arch Med Sci 2014; 10: 19-24.
- [100] Lin YY, He B, Chen J and Wang ZN. Can dexmedetomidine be a safe and efficacious sedative agent in post-cardiac surgery patients? a meta-analysis. Crit Care 2012; 16: R169.
- [101] Blaudszun G, Lysakowski C, Elia N and Tramer MR. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology 2012; 116: 1312-1322.
- [102] Carlisle JB and Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2006; Cd00-4125.
- [103] Massad IM, Mohsen WA, Basha AS, Al-Zaben KR, Al-Mustafa MM and Alghanem SM. A balanced anesthesia with dexmedetomidine decreases postoperative nausea and vomiting after laparoscopic surgery. Saudi Med J 2009; 30: 1537-1541.
- [104] Eisenach JC, Shafer SL, Bucklin BA, Jackson C and Kallio A. Pharmacokinetics and pharmacodynamics of intraspinal dexmedetomidine in sheep. Anesthesiology 1994; 80: 1349-1359.